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Parkinson’s disease (PD) is a complex neurodegenerative disorder. This research compared 
the characterisation of cognitive functioning, motor symptoms and non-motor symptoms in 
PD by the interRAI-Home Care Assessment (interRAI-HC) with a battery of detailed 
neuropsychological tests. A small sample of 34 participants were classified by cognitive 
status (PDN= Normative cognition, PDMCI=Mild Cognitive Impairment, PDD=Dementia) 
using current Movement Disorder Society criteria to evaluate whether the interRAI-HC could 
identify differences of functioning for these groups to reflect the differences of need indicated 
by research. This comparison also provided preliminary evaluation of the external validity of 
some corresponding interRAI-HC measures in the assessment of PD. Results of the 
interRAI-HC saw trends of agreement with neuropsychological testing, however very few 
measures distinguished significant group differences. The interRAI-HC assessment of falls, 
instrumental activities of daily living, short-term memory and procedural memory showed 
convergence with neuropsychological measures. However further research is required to 




Characterising Parkinson’s disease in the interRAI-Home Care Assessment 
 
Parkinson’s disease (PD) is a common and complex neurodegenerative disorder, long 
characterised by motor features of bradykinesia, postural instability, rigid gait and tremor.  
PD is also increasingly recognised as heterogeneous, with variable early clinical 
presentations and clinical outcomes (Jankovic, et al., 1990; Noyce, et al, 2012; Postuma, et 
al, 2012). Recent research shows that clinically significant non-motor symptoms can precede 
motor symptoms by more than a decade (Kalia and Lang, 2015), have greater impact on 
quality of life (Antonini, et al., 2012), and are associated with early mortality (Oosterveld, et 
al., 2015). Cognitive decline and dementia have moved to the forefront of recent PD 
research, because early cross-sectional studies reporting an average incidence of dementia 
in Parkinson’s disease (PDD) at 30-40% (Emre, et al., 2007) has evolved to an awareness 
that PDD eventuates in 75-90% of individuals as the disease progresses (Hely, Reid, Adena, 
Halliday and Morris, 2008). Recently published criteria has characterised cognitive profile in 
PD to three levels of cognitive status, patients with normal cognition (PDN), mild cognitive 
impairment (PDMCI) and PDD (Emre et al., 2007; Litvan, et al., 2012). This increased 
interest has given focus to the potential transitional phase of PDMCI which exhibits 
increased risk of progression to dementia (Hoogland, et al., 2017; Wood et al., 2016) and 
more aggressive motor decline (Louis, et al., 1999). As a result, researchers now 
recommend routine cognitive assessment in the management of PD to identify patients with 
a high risk of rapid cognitive decline with important implications for clinical care and 
intervention (Ambrosio, Narvarta-Sanchez and Portillo, 2014).  
Clinical care and intervention for chronic illness is a concern for policy makers worldwide 
(World Health Organisation, 2011) with PD projected to double in New Zealand in the next 
25 years (Myall et al., 2017) largely due to the increasing aging population. Thus 
assessment of PD patients by an interdisciplinary team of health professionals is important 
to understand the complexity of need across course, to implement and integrate 
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multidisciplinary intervention, to provide adequate community support, and to monitor 
projections of resources in order to meet this need. The interRAI Home Care (interRAI-HC) 
Assessment System is a validated comprehensive geriatric assessment designed to guide 
assessment of health needs, and the planning of care and services in community based 
settings (Morris et al., 2009). The advent of mandatory implementation of the interRAI-HC 
assessment in New Zealand presents an extraordinary opportunity to evaluate the 
characterisation of health needs for older people on a national scale and develop projections 
needed for adequate intervention (Nishtala and Jamieson, 2017). As part of this work, it is 
important to continue evaluation of how the interRAI-HC identifies the need of older people 
in the community, and specifically the complex needs of PD. 
 
1.1. Parkinson’s disease presentation 
Classic symptoms include rigidity and bradykinesia, although rest tremor is often an initial 
problem that leads to clinical assessment. In particular, the first two motor impairments are 
associated with early prominent loss of dopaminergic neurons in the substantia nigra (Braak 
et al. 2003). Degeneration and neuropathological changes across serotinergic, 
noradrenergic, and cholinergic neurotransmitter pathways, also contribute to motor deficits 
(Braak et al. 2003; Jellinger, 2012). However symptomology is often variable and 
unpredictable, with a constellation of motor and non-motor symptoms identified throughout 







Figure 1-1: Clinical symptoms and course of PD progression (Kalia and Lang, 2015) 
Note: Diagnosis of PD occurs with the onset of motor symptomology (Time= 0 years). However there 
is a constellation of motor and non-motor symptoms that contribute to disability, and hypothesised 
non-motor symptoms which can precede diagnosis by up to 20 years (Postuma et al., 2012). Motor 
symptoms, such as postural instability with frequent falls and freezing gait tend to occur later in the 
disease. Long-term complications of pharmacological intervention also contribute to fluctuations in 
symptom presentation, dyskinesia and psychosis. EDS = excessive daytime sleepiness. MCI = Mild 
Cognitive Impairment. RBD= REM sleep behaviour disorder. 
 
1.1.1.  Clinical characteristics and motor symptoms 
Clinical diagnosis of PD is based on a combination of cardinal motor symptoms: 
bradykinesia, rigidity and rest tremor (Table 1; Postuma, et al., 2015). In general, an 
individual may not experience all the cardinal motor features at diagnosis, and symptoms 
have different rates of progression, with faster disease progression in individuals with rigidity 
and bradykinesia than in those with predominant tremor (Jankovic et al. 1990). Early motor 
symptoms may include lugubrious or stiff facial expression, flexion of one arm with lack of 
swing while walking, monotonous quality of speech, or extreme slowing of movement. These 
early changes can be subtle, often going unnoticed by the patient or those around them, and 
become ascribed to aging. In late stages of the disease the face is often masked and 
expressionless, speech can be monotonous and slightly slurred, posture is flexed, and a pill 







 MDS clinical diagnostic criteria for Parkinson’s disease (Postuma et al., 2015) 
A. Diagnosis of Parkinsonian Syndrome 
Bradykinesia (i.e. slowness of initiation of voluntary movement with progressive reduction in speed 
and amplitude of repetitive actions)  plus one or more of the following features: 
- Muscular rigidity 
- 4-6 Hz rest tremor 
- Postural instability not caused by primary visual, vestibular, cerebellar or proprioceptive 
dysfunction 
B. Exclusion criteria for Parkinson’s disease 
One or more of the following features suggest an alternative diagnosis: 
- History of repeated strokes with stepwise progression of parkinsonian features 
- History of repeated head injury 
- History of encephalitis 
- Neuroleptic treatment at onset of symptoms 
- 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (MPTP) exposure 
- Negative response to large doses of Levodopa (if malabsorption excluded) 
- More than one affected relative (criteria generally no longer applied) 
- Sustained remission 
- Strictly unilateral features after 3 years 
- Early severe autonomic involvement  
- Early sever dementia with disturbances of memory, language and praxis 
- Oculogyric crises 
- Supranuclear gaze palsy 
- Babinski sign 
- Cerebellar signs 
- Presence of a cerebral tumour or communication hydrocephalus on CT or MRI 
C. Supportive prospective positive criteria for Parkinson’s disease 
Three or more of the following features are required for diagnosis of definite Parkinson’s disease 
- Unilateral onset 
- Rest tremor present 
- Progressive disorder 
- Persistent asymmetry affecting the side of onset most 
- Excellent response (70%-100%) to Levodopa 
- Severe Levodopa-induced chorea 
- Levodopa response for 5 years or more 
- Clinical course of 10 years or more 
 
1.1.2. Cognition in Parkinson’s disease 
Despite its prominence in research, a definitive cognitive profile in PD is difficult to establish 
(Kehagia, Barker and Robbins, 2010) and distinguishing a PD dementia profile from other 
neurodegenerative pathologies such as Lewy body dementia (DLB) and Alzheimer’s disease 
(AD) remains troublesome (Emre et al., 2007). Identification of early cognitive impairment is 
of particular importance (Litvan et al., 2012) and is associated with increased caregiver 
burden (Jones et al., 2017), nursing home admission (Aarsland et al., 2001), hallucinations 
(Korczyn, 2001) and mortality (Marder et al., 1991). Establishing early decline is essential in 
5 
 
order to begin treatment, allocate support, and to develop new interventions which may 
improve clinical outcomes. 
1.1.2.1. Cognitive characteristics 
A wide variety of cognitive impairments have been reported in PD, including impaired 
attention, memory, visuospatial function and executive functioning (Marder, 2010; 
Dalrymple-Alford et al., 2011; Troster, 2011). The ability to maintain attention and vigilance is 
impaired in PDD and may fluctuate more than attentional deficits seen in AD (Ballard et al., 
2002). Memory complaints in PDD are reported less often compared to other forms of 
dementia; with 67% of those with PDD reporting impaired memory compared to 90% of 
those with DLB and 100% of those with AD (Noe et al., 2004). Some suggest the memory 
deficit in PDD is one of retrieval, rather than encoding and storage (Emre et al., 2007), 
however there is a growing body of evidence showing recognition memory deficits in PDD on 
both verbal and non-verbal tasks (Whittington et al., 2000). Visuospatial functioning is 
substantially impaired in PD and appears worse than AD (Mosimann et al., 2004), with a 
marked impairment of construction and praxis (Cahn-Weiner, et al., 2003). However the 
cognitive profile of PDD is often understood as primarily an impairment of executive 
functioning, and deficits of memory or visuospatial processing may be more closely 
associated with executive dysfunction than individuals with AD (Emre et al. 2007). 
1.1.2.2. Mild Cognitive Impairment and Dementia 
Recently published guidelines by the Movement Disorders Society Task Force (MDS) have 
proposed diagnostic criteria for PDMCI (Table 2; Litvan et al., 2012). Two levels of 
assessment are suggested which require established cognitive decline that does not 
significantly interfere with functional independence. Level I consists of a brief assessment 
demonstrating impairment on measures of global cognition, or impairment on one or two 
specific measures across five cognitive domains (attention, memory, visuospatial 
functioning, executive functioning and language). Level II assessment proposes more 
comprehensive criteria, with impairment established in at least two measures across 
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attention, memory, visuospatial functioning, executive functioning and language. Impairment 
is required on at least two neuropsychological tests within one or two of these cognitive 
domains. That said, the level of impairment is not fixed and within 1 or 2 standard deviations 
below normative data. Recent published research examining these options proposed that, to 
capture a heightened risk of developing dementia in a 4 year period, optimal PDMCI criteria 
should identify at least two impairments at 1.5 standard deviations below the normal range 
within a single cognitive domain (Wood et al., 2016). 
Table 1-2 
Criteria for the diagnosis of PDMCI (Litvan et al., 2012) 
I. Inclusion criteria 
a. Diagnosis of Parkinson’s disease as based on the Queen’s Square Brain Bank criteria 
b. Gradual decline, in the context of established PD, in cognitive ability reported by either the 
patient or informant, or observed by the clinician 
c. Cognitive deficits are either formal neuropsychological testing or a scale of global 
cognitive abilities (detailed in section III) 
d. Cognitive deficits are not sufficient to interfere significantly with functional independence, 
although subtle difficulties on complex functional tasks may be present 
II. Exclusion criteria 
a. Diagnosis of PD dementia based on the MDS task force proposed criteria (Emre et al., 
2007). 
b. Other primary explanations for cognitive impairment (e.g. delirium, stroke, major 
depression, metabolic abnormalities, adverse effects of medication, or head trauma) 
c. Other PD-associated comorbid conditions (e.g. motor impairment or severe anxiety, 
depression, excessive daytime sleepiness, or psychosis) that, in the opinion of the clinician, 
significantly influence cognitive testing 
III. Specific guidelines for PDMCI level I and level II categories 
A. Level I (abbreviated assessment) 
- Impairment on a scale of global cognitive abilities validated for use in PD or 
- Impairment on at least two tests, when a limited battery of neuropsychological 
tests is performed (i.e. the battery includes less than two tests within each of the 
five cognitive domains, or less than five cognitive domains are assessed) 
B. Level II (comprehensive assessment) 
- Neuropsychological testing that includes two tests within each of the five 
cognitive domains (i.e. attention and working memory, executive, language, 
memory and visuospatial) 
- Impairment on at least two neuropsychological tests, represented by either two 
impaired tests in one cognitive domain or one impaired test in two different 
cognitive domains 
- Impairment on neuropsychological tests may be demonstrated by: 
o Performance approximately 1 or 2 SDs below appropriate norms or 
o Significant decline demonstrated by serial cognitive testing or 
o Significant decline from estimated premorbid levels 
IV. Subtype classification for PDMCI (optional, requires two tests for each of the five 
cognitive domains assessed and is strongly suggested for research purposes) 
- PDMCI single domain –abnormalities on two tests within a single cognitive 
domain (specify the domain), with other domains unimpaired or 
- PDMCI multiple domain –abnormalities on a least one test in two or more 
cognitive domains (specify the domains) 
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Diagnosis of dementia is established if there are significant deficits in at least two cognitive 
domains, which disrupt normal daily functioning (Table 2; Emre et al., 2007). This cognitive 
impairment must also occur with established PD motor symptomology in order to distinguish 
PDD from DLB pathology. To distinguish impairment which may have been caused by 
another symptom or condition other than PDD, the MDS has also proposed criteria for 
“probable: PDD and “possible” PDD (Table 3; Emre et al., 2007). When the time interval 
between the development of motor symptoms and significant loss of everyday functional 
independence is unknown, a diagnosis of possible PDD is preferable to probable PDD, 
unless a diagnosis of DLB is more likely (McKeith and Mosimann, 2004). 
Table 1-3 
Features of dementia associated with Parkinson’s disease (Emre et al., 2007) 
II. Core features 
a. Diagnosis of Parkinson’s disease according to the Queen’s Square Brain Bank criteria 
b. A dementia syndrome with insidious onset and slow progression, developing within the 
context of established Parkinson’s disease and diagnosed by history, clinical and mental 
examination, defined as: 
i. Impairment in more than one cognitive domain 
ii. Representing a decline from premorbid level 
iii. Deficits severe enough to impair daily life (social, occupational, or personal care), 
independent of the impairment ascribable to motor or autonomic symptoms 
III. Associated clinical features 
a. Cognitive features: 
i. Attention: Impaired. Impairment in spontaneous and focused attention, poor 
performance in attentional tasks; performance may fluctuate during the day and 
from day to day 
ii. Executive functioning: Impaired. Impairment in tasks requiring initiation, 
planning, concept formation, rule finding, set shifting or set maintenance; 
impaired mental speed (bradyphrenia) 
iii. Visuospatial functioning: Impaired. Impairment in tasks requiring visual spatial 
orientation, perception, or construction 
iv. Memory: Impaired. Impairment in free recall of recent events or in tasks requiring 
learning new material, memory usually improves cueing, recognition is usually 
better than free recall 
v. Language: Core functions largely preserved. Word finding difficulties and 
impaired comprehension of complex sentences may be present 
b. Behavioural features: 
i. Apathy: decreased spontaneity; loss of motivation, interest and effortful behaviour 
ii. Changes in personality and mood, including depressive features and anxiety 
iii. Hallucinations: mostly visual, usually complex, formed visons of people, animals 
or objects 
iv. Delusions: usually paranoid, such an infidelity or phantom boarder (unwelcome 
guests living in the home) delusions 
v. Excessive daytime sleepiness 
IV. Features which do not exclude PDD, but make diagnosis uncertain 
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i. Co-existence of any other abnormality which may be itself cause cognitive 
impairment, but judged not to be the cause of dementia, e.g. presence of relevant 
vascular disease in imaging 
ii. Time interval between the development of motor and cognitive symptoms not 
known 
V. Features suggesting other conditions or diseases as cause of mental impairment, which 
present make it impossible to reliably diagnose PDD 
i. Cognitive and behavioural symptoms appearing solely in the context of other 
conditions such as: 
Acute confusion due to: 
a. Systematic diseases or abnormalities 
b. Drug intoxication 
Major depression according to DSM-5 
ii. Features compatible with “Probable Vascular dementia” criteria according to 
NINDS-AIREN (dementia in the context of cerebrovascular disease as indicated 
by focal signs in neurological exam such as hemiparesis, sensory deficits, and 
evidence of relevant cerebrovascular disease by brain imagine and a relationship 
between the two as indicated by the presence of one or more of the following: 
onset of dementia within 3 months after a recognised stroke, abrupt deterioration 




Table 1-4  
Criteria for the diagnosis of Probable and Possible PDD (Emre et al., 2007) 
Probable PDD 
A. Core features: Both must be present 
B. Associated clinical features: 
- Typical profile of cognitive deficits including impairment in at least two of the four 
core cognitive domains (Impaired attention which may fluctuate, impaired executive 
functioning, impaired visuo-spatial functions, and impaired free recall memory which 
improves with cueing) 
- The presence of at least one behavioural symptom (apathy, depressed or anxious 
mood, hallucinations, delusions, excessive daytime sleepiness) supports the diagnosis 
of Probably PDD, lack of behavioural symptoms, however, does not exclude 
diagnosis 
Possible PDD 
A. Core features: Both must be present 
B. Associated clinical features: 
- Atypical profile of cognitive deficits including impairment in one or more domains, 
such as prominent or receptive-type (fluent) aphasia, or pure storage-failure type 
amnesia (memory does not improve with cueing or in recognition tasks) with 
preserved attention 
- Behavioural symptoms may or may not be present 
                   OR  
C. One of more of the group III features present 
D. None of the group IV features present 
 
1.1.3. Additional non-motor symptoms 
PD presents with a heterogeneous constellation of non-motor symptoms (Zhang et al., 2015; 
Marras and Chaudhuri, 2015). Early non-motor features include impaired olfaction, 
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constipation, depression, excessive daytime sleepiness, and rapid eye movement sleep 
behaviour disorder (Kalia and Lang, 2015). Constipation and mood appear to approximately 
double an individual’s risk of subsequent PD (Noyce et al., 2012) and significant increased 
risk is also seen in those who have never smoked (Ascherio et al., 2003). As the disease 
progresses, patients experience increased falls (Wielinski, et al., 2005), chewing and 
swallowing difficulties, drooling of saliva, and incontinence complaints (Pandya, Kubu and 
Giroux, 2008). Due to the large array of non-motor symptoms across the course of PD, 
comprehensive assessment across multiple domains related to health is essential to 
accurately meet the need of patients (Chaudhuri, Yates and Martinez-Martin, 2005). 
1.1.3.1. Functional independence –Activities of Daily Living 
Motor and cognitive symptoms in PD affect functional independence and a patient’s ability to 
complete daily activities (Guttman et al., 2003). Low degree of functional independence has 
a significant impact on PD severity, prognosis, self-reported distress, and well-being for 
patients with PD (Herlofson, and Larsen, 2003). Additionally, reduced functional 
independence has a greater burden on caregivers than motor symptoms (Leiknes, Lien and 
Severinsson, 2015).  
Functional independence is measured as both Activities of Daily Living (ADLs) and 
Instrumental Activities of Daily Living (IADL). ADL activities are related to personal care, 
including bathing, dressing and eating (World Health Organisation, 2001). IADLs relate to 
more complex activities which require a higher level of personal autonomy, such as meal 
preparation, managing medications or managing finances (World Health Organisation, 
2001). In PD it is important to establish whether functional independence is compromised 
due to motor ability or cognitive impairment, and is a distinguishing factor between PDMCI 
and PDD (Litvan et al., 2012; Emre et al., 2007). 
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1.1.3.2. Neuropsychiatric symptoms – Mood and Behaviour 
Depression is a common feature across the course of PD, with prevalence rates varying 
between 7% and 70% (Burn, 2002). In later stages of the disease apathy (Pedersen et al., 
2011), anxiety (Alamri, et al., 2015), and hallucinations and delusions (Weintraub et al, 2006) 
are common. Symptoms of depression and apathy can be subtle due to the masked facial 
expression symptomatic of PD, but can have a major impact on the quality of life of patients 
and their caregivers (Jones et al., 2017), and may negatively influence cognitive functions 
(Scheider, Sendak, and Yang, 2015).  
1.2. interRAI-Home Care Assessment 
interRAI stands for ‘International Resident Assessment Instrument’ and the name refers to 
both a suite of assessment instruments and to the organisation that develops them (Gordon, 
2008). There are several interRAI assessment protocols across public health services (such 
as Acute Care, Long-Term Care, Palliative Care, and Intellectual Disability) and the 
assessments are being used in around 22 countries throughout the world (Morris et al, 
2009). The interRAI-HC assessment focuses on a person’s functioning and quality of life by 
assessing health needs, and facilitates appropriate referrals and intervention (Burrows et al., 
2000). It has been established as a reliable assessment tool (Morris et al., 1997; Hirdes et 
al., 2008; Burrows et al., 2000; de Almeida, et al., 2015; Parsons et al., 2013; Kim et al., 
2015) and when used in multiple assessments can be used to evaluate a person’s 
developing need and response to care services (Morris et al., 2009). The assessment 
evaluates multiple key domains, including: cognition, communication and vision, mood and 
behaviour, psychosocial well-being, functional status, continence, nutrition, and social 
support (see Appendix A and Appendix B for interRAI-HC assessment). In addition, it 
aggregates data across several internal outcome measures established to assess cognition 
(Cognitive Performance Scale; Morris et al., 1994), depression (Depression Rating Scale; 
Burrows et al., 2000), activities of daily living (Morris, Fries and Morris, 1999) and pain (Fries 
et al., 2001). These outcome scales propose to highlight and summarise the health need of 
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an individual and have been developed to provide valid and reliable descriptions of older 
person’s health (Morris et al., 2000). 
In 2003, the NZ Guidelines Group (NZGG) noted dissatisfaction between best and actual 
assessment processes and practices for older person’s health within New Zealand (NZGG, 
2003). Critical evaluation of available comprehensive assessments was completed (Martin 
and Martin, 2003) and the NZGG recommended that the interRAI-HC assessment be 
applied as the nationwide standard of assessment in the elderly (2003). Subsequently, five 
District Health Boards across New Zealand piloted the interRAI-HC (Weidenbhom et al., 
2006) and a version of the instrument was developed for use with older persons at risk of 
admission into aged residential care or requiring long-term support. The interRAI-HC has 
been in use in community care assessment in New Zealand since 2012, and is now 
mandated to ascertain a person’s level of need, to develop a care plan, and to identify 
appropriate services and support options (Ryall, 2013). Referred by general health 
practitioners, community health workers, or hospital based health professionals, interRAI-HC 
assessments are conducted by trained health professionals (mainly nurses and social 
workers) and are completed mostly in the home. The instrument itself is not designed for or 
accommodates the assessment of any specific disease or condition, and is not a diagnostic 
tool (Morris et al, 2009). However current diagnoses are noted within the assessment, to 
document conditions which may impact ADLs, cognition, mood and behaviour, need for 
monitoring or risk of death (Morris et al, 2009). 
It is anticipated that 46,000 home care assessments will be performed annually (Schluter et 
al., 2016), and although information is primarily to inform personal care decisions, 
opportunities exist to better understand older person’s health and health care needs on a 
national level (Nishtala and Jamieson, 2017). Because frail older persons usually have 
complex and challenging health needs, home care services should be adapted to meet this 
population (Parsons et al., 2013). As a dominant chronic disease amongst our older 
population, a suitable comprehensive evaluation for PD is essential in order to accurately 
determine community need. 
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1.3. Aim of the current study 
The current study examines the characterisation of cognitive functioning, motor symptoms 
and non-motor symptoms for PD using the interRAI-HC. A small sample of individuals were 
identified by detailed neuropsychological testing as PDN, PDMCI and PDD, so that the 
relevance of the interRAI-HC could be evaluated for these groups. Characterisation of PD 
will be compared between results of detailed neuropsychological testing and elements of the 
interRAI-HC. It is expected that detailed neuropsychological testing will distinguish clinical 
characteristics, cognitive functioning, activities of daily living, and symptoms of mood and 
behaviour for this sample by cognitive status. It is the aim of this study to ascertain whether 
the interRAI-HC can similarly distinguish these groups from measures of cognition, activities 
of daily living, or mood and behaviour. This study will also explore whether detailed 
neuropsychological testing and cognitive status can validate some aspects of the interRAI-
HC for the PD population, such as cognition or activities of daily living. This study will 
examine individual items within sections of the interRAI-HC as well as aggregate outcome 
measures developed within the instrument.  
 2. Method 
2.1. Participants  
Participants were recruited following ethical approval from the Southern Health and Disability 
Ethics Committee as part of the NZBRI longitudinal progression study (NZBRI study; 
URB/09/08/037/AM02). Figure 2-1 outlines the sample selection process for this study. 
Participants were selected from 1) the existing participant database of the NZBRI study 
(NZBRI database) and 2) through a specialised clinic for Parkinson’s disease (Clinic 
database). For final inclusion in this study, participants were required to have received both 
detailed neuropsychological testing conducted at NZBRI and a Canterbury District Health 
















a Existing participants of Progressive Changes of Potential Indicators in Parkinson’s Disease (NZBRI 
study), a longitudinal study of NZBRI. In this study, Parkinson’s disease participants were recruited 
from the Van Der Veer clinic, a specialist clinic for individuals with Parkinsonian symptomology, and 
required a diagnosis of Parkinson’s disease and to be aged between 65-85 years old. Exclusion 
criteria included a current diagnosis of dementia, history of moderate or severe head injury, history 
of stroke or neurosurgery, an active major medical illness which could impact participation (i.e. 
cancer treatment), recent psychiatric illness requiring hospitalisation, major depression diagnosis in 
the last 6 months and a history of renal disease.  
b Complete interRAI-HC assessments identified by NHI number through the Canterbury District 
Health Board (CDHB).  
c Both neuropsychological testing and interRAI-HC assessment completed within 183 days (6 
months). 
d Individuals had completed an interRAI-HC assessment within 120 days (4 months) and could 
potentially be recruited to complete neuropsychological assessment within 183 day criteria. 
e Participants of the NZBRI study who were excluded from additional neuropsychological testing for 
this research; n=2 declined participation, n=2 unable to complete testing within 183 days, n=1 too 
unwell to participate. 
f Clients who had not yet been approached for participation in the NZBRI study and gave consent to 
be contacted for participation in research of this nature. 
g Successfully approached and completed detailed neuropsychological test battery at NZBRI within 
183 days of recent interRAI-HC; n=3 existing participants from NZBRI study, n=3 new participants 
from clinic database. 
h Individuals who were excluded from recruitment to the NZBRI study; n=2 did not meet Parkinson’s 
disease diagnosis, n=2 too unwell to participate, n=2 declined participation, n= 1 interRAI-HC could 
not be located, n=1 could not be recruited and tested on neuropsychological battery within 183 
days.  
i Data received from the CDHB; n=34 complete interRAI=HC assessments and n=31 of the interRAI-
HC Outcome Measure data. 
j  Criteria for Parkinson’s disease normative cognition group (PDN): Intact cognition and memory 
impairments normative to age and education as shown by scores >-1.5 SD of standardised norms, 
or a score -1.5 SD below standardised norms in less than two tests in any single cognitive domain. 
k Criteria for Parkinson’s Disease with mild cognitive impairment group (PDMCI): 1) Objective 
memory impairment on two or more tests (score -1.5 SD below standardised age and education 
corrected normative data) in a single cognitive domain; 2) at least one impaired global mental status 
score from MoCA (<26), DRS-2 (scaled score of <9) or ADAS-Cog (>9); 3) subjective memory 
complaint by participant or informant on the CDR; and 4) exclusion of dementia criteria on the CDR 
as a score of 0 – 0.5 and preserved activities of daily living judged by significant other and/or the 
interviewer.  
l  Criteria for Parkinson’s Disease with dementia group (PDD): 1) Significant cognitive impairment on 
two or more tests (score -2 SD below standardised age and education corrected normative data) in 
multiple cognitive domains; at least one impaired global mental status score from MoCA (<22), 
DRS-2 (scaled score of <6) or ADAS-Cog (>15); 3) subjective memory complaint by participant or 




Participants of the NZBRI study (Figure 2-1: NZBRI database) were verified via National 
Heath Index number (NHI) whether they had completed neuropsychological testing and an 
interRAI-HC assessment within six months. Of the 414 active participants in the NZBRI 
study, 54 had completed an interRAI-HC assessment, and 28 participants had received both 
interRAI-HC and neuropsychological testing within 183 days (six months). An additional 
eight participants were selected having completed a recent interRAI-HC assessment with 
potential to receive neuropsychological testing within 183 days. Three of those participants 
were successfully given detailed neuropsychological testing through NZBRI. Five 
participants were excluded as they declined neuropsychological assessment (n= 2), were 
unable to receive testing within 183 days of their interRAI-HC (n= 2) or were too unwell to 
participate (n=1).  
The client database from the Van Der Veer clinic for Parkinson’s disease (Figure 2-1: Clinic 
database) were also reviewed and 11 clients were identified to have had received a recent 
interRAI-HC and had given consent to be contacted for future research. Of this recruitment 
drive, three participants were successfully enlisted into the study and received detailed 
neuropsychological testing within 183 days of their interRAI-HC assessment. Eight potential 
participants were excluded from the study as they were too unwell to participate (n= 2), did 
not meet Parkinson’s disease diagnosis (n=2), declined participation (n=2), their interRAI-HC 
could not be located (n= 1), or they were unable to complete testing within 183 days of their 
interRAI-HC (n= 1). 
The final sample of 34 participants were classified on the basis of their cognitive 
performance and assessment of everyday function (Figure 2-1). Participants were identified 
as showing cognitive function within the normal range (PDN; n= 12), with mild cognitive 
impairment (PDMCI; n= 9) PDMCI or with dementia (PDD; n= 13). Table 2-1 summarises the 
demographics of the three groups, including median and upper and lower bounds of the 





Demographics of participants (n=34) 
 PDN (n= 12) PDMCI (n=9) PDD (n=13) 
 Md (Q1, Q3) Md (Q1, Q3) Md (Q1, Q3) 
Age 71.0 (70.0, 74.0) 75.0 (70.5, 77.0) 76.0 (71.0, 78.3) 
Education (yrs) 12.0 (10.5, 12.0) 11.0 (10.0, 13.0) 14.0 (11.8, 15.3) 
Disease Duration (yrs) 8.0 (6.0, 12.0) 8.0 (2.5, 11.25) 10.0 (6.8, 11.8) 
Male/ Female 8 / 4  7 / 2  9 / 4 
NZ European/ Other 
European/ Asian 
9 / 3 / 0  8 / 0 / 1  10 / 3 / 0 
Note: Md = Median; Q1 = Lower Quartile; Q3= Upper Quartile 
Inclusion criteria for the PDN group was that they did not meet NZBRI criteria for PDMCI. 
Participants were identified as PDMCI if: 1) there was an objective impairment on two or 
more tests at a score -1.5 SD below standardised age and education corrected normative 
data within a single cognitive domain; 2) at least one impaired global mental status score 
from Montreal Cognitive Assessment (MoCA; <26), Dementia Rating Scale-2 (DRS-2; 
scaled score of <9) or Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-
Cog; >9), 3) a subjective memory complaint by participant or informant on the Clinical 
Dementia Rating scale (CDR) of 0 or 0.5, and 4) largely preserved instrumental activities of 
daily living judged by significant other and/or the interviewer.  
Criteria for the PDD group required: 1) significant cognitive impairment on any tests across 
at least two cognitive domains (score -2 SD below standardised age and education 
corrected normative data); 2) at least one impaired global mental status score from MoCA 
(<22), DRS-2 (scaled score of <6) or ADAS-Cog (>15); and 3) compromised activities of 
daily living, including 1 or more on the CDR or >1.5 on the Activities of Daily Living –
International Scale (ADL-IS).  
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2.2. Comprehensive Assessment 
2.2.1. Detailed neuropsychological assessment  
As described below, detailed neuropsychological testing included clinical measures of 
Parkinson’s disease, neuropsychiatric measures, and both global scales and individual tests 
of cognition across five cognitive domains (MDS recommendations; Litvan et al., 2012). 
Neuropsychological assessment was administered by a trained research assistant at NZBRI 
with strict adherence to standardised scripts and scoring. 
2.2.1.1. Clinical Assessment of Parkinson’s disease 
The Unified Parkinson’s Disease Rating Scale (UPDRS; Goetz, et al., 2008) and the Hoehn 
and Yahr Staging of Parkinson’s disease (H&Y; Goetz, et al., 2004) were given to assess 
clinical characteristics associated with Parkinsonian pathology. 
2.2.1.2. Global Functioning 
The Mini-Mental Status Examination (MMSE; Folstein, et al., 1975; Mitchell, 2009), Montreal 
Cognitive Assessment (MoCA; Nasreddine, et al., 2005; Dalrymple-Alford, et al, 2010), 
Alzheimer’s Disease Assessment Scale –Cognitive Subscale (ADAS-Cog; Rosen, Mohs, 
and Davis, 1984; Grochowalski, et al., 2016), Dementia Rating Scale -2 (DRS-2; Jurica, et 
al., 2001; Aarsland et al., 2003; Matteau, et al., 2012) and Activities of Daily Living-
International Scale (ADL-IS; Reisberg, et al., 2001) assessments were also given to assess 
global cognition and everyday functioning. 
2.2.1.3. Attention, Working Memory and Processing Speed 
To assess attention, working memory and processing speed, participants completed 
subtests of digit span (WAIS-IV; Digit forwards/backwards; Digit Ordering; Weschler, 2008a, 
2008b), the Test of Everyday Attention –Map Search (TEA; Robertson, et al., 2001), the 
Delis-Kaplan Stroop task (Stroop Colour and Word naming; DKEFS; Delis, Kaplan & 
Kramer, 2001) and trail making task (Trails A; DKEFS; Delis, Kaplan & Kramer, 2001). 
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2.2.1.4. Executive Function 
The assessment of executive functioning involved several subtests from the Delis-Kaplin 
Executive Functioning Scale (DKEFS; Delis, Kaplan & Kramer, 2001), including the letter 
fluency, action fluency and category fluency tasks, category switching task, the Stroop colour 
word interference task and the Trail B symbol digit modality task.  
2.2.1.5. Learning and Memory 
Learning and memory was examined using the short form of the California verbal learning 
test (DKEFS; CVLT; Delis, Kramer, and Ober, 2000) and the Rey-Osterrieth Complex Figure 
(RCFT; Meyers and Meyers, 1995). 
2.2.1.6. Visuospatial Functioning 
Visual spatial functioning was tested using the Judgement of Line Orientation test (JLO; 
Benton, Hannay, and Varney, 1975), the Visual Object and Space Perception Test (VOSP; 
Warrington and James, 1991), the picture completion subset (WAIS-IV; Weschler, 2008a, 
2008b) and the visual-construction copy task of the Rey- Osterrieth Complex Figure test 
(RCFT –Copy; Meyers and Meyers, 1995). 
2.2.1.7. Language 
Language was assessed using the Boston naming test (Kaplan, Goodglass & Weintraub, 
1983), the language measure for the Alzheimer’s Disease Assessment Scale –Cognitive 
Subscale (ADAS-Cog; Rosen, Mohs, and Davis, 1984) and the Dementia Rating Scale 
(DRS-2; Jurica, et al., 2001). 
2.2.1.8. Neuropsychiatric measures 
The Neuropsychiatric Inventory (NPI; Cummings, 1997; de Medeiros, et al., 2010), Geriatric 
Depression Scale (GDS; Brink et al., 1992), and Hospital Anxiety and Depression Scale 
(HADS; Zigmond and Snaith, 1983; Norton, et al., 2013) were given to assess behavioural 
and psychiatric symptomology. 
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2.2.2. interRAI-Home Care Assessment 
The interRAI-HC is a standardised screening tool, designed for clinical use (interRAI, 2009). 
The assessment consists of 236 questions which are divided into 20 domains: A: 
Identification Information, B: Intake and Initial History, C: Cognition, D: Communication and 
Vision, E: Mood and Behaviour, F: Psychosocial Well-being, G: Functional Status, H: 
Continence, I: Disease Diagnosis, J: Health Conditions, K: Oral and Nutritional Status, L: 
Skin Condition, M: Medications, N: Treatment and Procedures, O: Responsibility, P: Social 
Support, Q: Environmental assessment, R: Discharge potential and Overall status. S: 
Discharge, and T: Assessment information. Data within the full assessment is then used 
form 27 Outcome scales, including the Cognitive Performance scale (CPS; Morris et al., 
1994), the Depression Rating scale (DRS; Burrows et al, 2000), and Activities of Daily Living 
scale (ADL –Long Form; IADL Performance Scale; IADL Capacity Scale; Morris, Fries and 
Morris, 1999) to characterise severity of symptomology, develop a profile of need for the 
individual and plan intervention.  
Two versions of the interRAI-HC form have been used within the CDHB and data from both 
forms were analysed within this study (see Table 2-3); the Minimum Data Set –Home Care 
assessment (MDS-HC version 2.0; Hirdes et al., 2000; Appendix B) and the interRAI-Home 
Care assessment (interRAI-HC Version 9.1 NZ customisation; interRAI, 2012; Appendix A).  
Data received from the MDS-HC was recoded to match the format of the interRAI-HC (see 
Appendix C). 
interRAI-HC data was retrieved through the CDHB using participant NHI and interRAI-HC 
assessment date. Data of the full interRAI-HC assessment was received for all participants 








Full assessment and outcome measure data received from the CDHB per version of the 
interRAI-HC 
 MDS-HC interRAI-HC Total 
Full Assessment data 18 16 34 
Outcome scale data 15 16 31 





3.1. Statistical analyses 
Due to the nature of the data in this study, a number of analyses, including non-parametric 
analyses, were employed to interpret results. Median (Md) and quartile range (Q1= Lower 
quartile; Q3 = Upper quartile) are used to describe the data, due to the expected distribution 
and small sample size. The Kruskal-Wallis test by ranks was used to test analysis of 
variance of group scores on the neuropsychological battery and outcome scores in the 
interRAI-HC, and post hoc analyses were completed using the Conover-Iman test. Fisher 
Exact tests were used to test group differences and complete post hoc analyses across 
nominal variables within the interRAI-HC. Correlational analyses between 
neuropsychological and interRAI-HC measures used Spearman’s rank correlation 
coefficient. Analyses were completed using the MedCalc statistical software package. 
3.2. Parkinson’s disease characterised by detailed neuropsychological testing 
Table 3-1 summarises the demographics of the sample and results of detailed 
neuropsychological testing measuring motor symptoms, global cognition, activities of daily 
living and neuropsychiatric symptoms in the three PD groups. Analysis of variance showed 
no significant group differences between age, education or duration of disease diagnosis. 
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However, the three groups differed significantly on global cognition measures and in 
activities of daily living, with increasingly poor scores from PD-N to PD-MCI and PDD 
(Conover-Iman post-hoc test, p<0.05). The PDD group generally exhibited worse measures 
of parkinsonism and motor symptoms, compared to the PD-N and PD-MCI groups, which did 
not differ. A significant group difference was observed in the Neuropsychiatric Inventory, but 
not in specific measures of anxiety or depression.  
Table 3-1 
Demographics, motor symptoms, global cognition, activities of daily living and neuropsychiatric 
characteristics of Parkinson’s disease patient sample (n=34) 
  
PDN 






  Md (Q1, Q3) Md (Q1, Q3) Md (Q1, Q3)  
Demographics       
Male / 
Female 
 8 / 4 7 / 2   9 / 4  
Age (yrs)  71.0 (70.0, 74.0) 75.0 (70.5, 77.0) 76.0 (71.0, 78.3) H(2)= 1.93; p=0.38 
Education 
(yrs) 
 12.0 (10.5, 12.0) 11.0 (10.0, 13.0) 14.0 (11.8, 15.3) H(2)= 4.01 , p=0.13 
Diagnosis 
Duration (yrs) 
8.0 (6.00, 12.0) 8.0 (2.5, 11.3) 10.00 (6.8, 11.8) H(2)=0.85, p=0.65 
Parkinsonian and motor symptoms      
H&Y 2.5 (1.5, 3.0) 2.3 (1.8, 2.5) 3.00 (2.5, 4.0) H(2)=5.96 p˂.05; c* 
UPDRS-I 7.0 (1.5, 14.5) 6.0 (3.0, 8.5) 11.5 (9.0, 21.0) H(2)=6.73, p˂.05; b*c* 
UPDRS-II 18.5 (11.5, 23.5) 12.4 (11.1, 15.7) 23.0 (17.9, 28.5) H(2)= 7.64, p˂.05; c* 
UPDRS-III 34.1 (22.3, 46.5) 26.4 (19.5, 36.1) 49.0 (14.5, 72.9) 
H(2)=10.88, p˂.01; b*** 
c*** 
Global measures of cognition      
MMSE 28.0 (27.0, 29.5) 26.0 (25.8, 28.0) 24.0 (22.0, 25.0) 
H(2)=20.19, p˂.001; a* b** 
c** 
MoCA 26.0 (25.5, 27.0) 23.0 (20.8, 25.0) 20.0 (15.5, 21.3) 
H(2)=21.42, p˂.001; a*** 
b*** c** 
ADAS-Cog 6.9 (5.1,  8.2) 10.0 (9.6, 13.4) 19.8 (16.6, 26.6) 
H(2)=22.33, p˂.001; a*** 
b*** c*** 
DRS -2 12.0 (10.0, 13.0) 10.0 (8.5, 11.5) 6.0 (3.75, 6.3) 
H(2)=23.28, p˂.001; a* 
b*** c*** 
Activities of Daily Living      
ADL-IS 0.3 (0.1, 0.6) 1.1 (0.4, 1.9) 1.9 (1.7, 2.5) 
H(2)= 18.25, p˂.001; a* 
b*** c*** 
Neuropsychiatric measures     
NPI 1.0 (0.0, 3.0) 3.0 (1.0, 6.0) 10.0 (6.5, 17.3) 
H(2)=8.15, p˂.05;  
b* c* 
GDS 1.0 (1.0, 1.0) 2.0 (2.0, 2.8) 4.0 (4.0, 5.0) H(2)= 0.93, p=0.53 
HADS -Anxiety 7.5 (1.0, 9.0) 8.0 (2.8, 10.3) 8.0 (7.3, 10.0) H(2)= 1.06, p=0.58 
HADS -Depression 5.0 (3.0, 7.0) 7.0 (4.8, 9.3) 7.0 (4.5, 8.0) H(2)= 1.119, p=0.57 
Note: Values are reported as median (Md), and the upper and lower bounds of the quartile range (Lower quartile= 
Q1; Upper quartile= Q3). Analyses/Analysis of variance: Kruskal-Wallis. Post hoc pairwise comparison/Conover-Iman 
test between: a= PDN v PDMCI; b= PDN v PDD; c= PDMCI v PDD; *p< 0.05; ** p< 0.01; ***p<0.005. 
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Significant group differences were also observed in all cognitive domains assessed by 
detailed neuropsychological testing (p<0.001). Table 3-2 summarises the median z-scores 
for each individual test per cognitive domain, and combined z-score for each cognitive 
domain.  Median z-scores for PDN did not fall below -1.0 on any measure in any cognitive 
domain, and domain scores tended to reflect unimpaired cognition relative to norms, except 
for the combined language z-score which appeared elevated. Results for PDMCI showed 
early cognitive impairment, with one median z-score on individual tests falling below -1.0 or -
2.0 in every cognitive domain except language, and in two tests of attention and working 
memory, and learning and memory. PDD median scores showed significant impairment, with 
several median z-scores of -3.0, indicating significant impairment and cognitive ability -3SD 
below expected norms.   
Group differences were observed in all individual tests except digits forward and backward 
(Digit F/B; Attention, Working memory and Processing speed) and the Boston Naming 
subtest (Language). PDD exhibited worse performance as compared to PDMCI on every 
measure of executive functioning (p<0.001), although PDN and PDMCI did not differ. Picture 
completion, a measure of visuospatial functioning, distinguished significant differences 
across all three groups (p<0.005).  
The three groups differed significantly across all combined cognitive domains, and a 
progressive decline of cognitive function can be seen between PDN compared to PDMCI, 
and PDMCI to PDD in attention and working memory, executive functioning, learning and 
memory, visuospatial functioning, language, and global cognition. Post hoc analyses 
supported this trend as PDD performed worse than PDN in all cognitive domains, and 
showed greater impairment compared to PDMCI in all cognitive domains except for 
visuospatial functioning. In this way, the global z-score, which is a combined aggregate of 
average scores on all tests in all cognitive domains, also showed significant progression of 




Table 3-2  
Cognitive characteristics per cognitive domain of the sample (n=34) 
 PDN                
(n = 12) 
PDMCI       
(n= 9) 
PDD              
(n= 13) 
Analyses 
 Md (Q1, Q3) Md (Q1, Q3) Md (Q1, Q3)  
Attention, Working Memory and Processing Speed     
Digits F/B  0.5 (0.2, 1.0) 0.3 (-0.2, 1.1) 0.0 (-1.1, 0.4) H(2)= 4.42; p= 0.11  
Digit Ordering  -0.5 (-1.7, 0.1)  -1.4 (-1.9, -0.3) -2.6 (-3.0, -2.0) H(2)= 13.40; p˂0.005; b*** c*** 
TEA (Map Search) -0.7 (-1.0, 0.0) -2.0  (-2.8, -1.6) -2.7 (-3.0, -2.2) H(2)= 18.51; p˂0.001; a*** b*** 
Stroop Colour   0.2 (-0.5, 0.3) -0.7 (-1.8, 0.3) -3.0 (-3.0, -1.3) H(2)= 14.56; p˂0.001; b*** c*** 
Stroop Word   0.0 (-0.5, 0.7)   0.0 (-1.3, 0.8) -1.0 (-2.3, -0.7) H(2)=  9.01;  p˂0.05; b* c* 
Trails A   0.4 (-0.3, 0.7) -0.5 (-1.6, 0.8) -3.0 (-3.0, -1.5) H(2)= 17.78; p˂0.005; b*** c*** 
Domain Score -0.1 (-0.5, 0.2) -0.7 (-1.2, -0.3) -1.9 (-2.2, -1.5) H(2)= 20.74; p˂0.001; b* c* 
Executive Function     
Letter Fluency   0.7 (0.0, 1.3)   1.0 (0.1, 1.6) -1.3 (-1.8, -0.5) H(2)= 13.39; p˂0.005; b*** c*** 
Action Fluency -0.7 (-1.1, 0.3) -1.7 (-2.3, -1.0) -2.5 (-3.0, 2.3) H(2)= 20.82; p˂0.001; b*** c*** 
Category Fluency   0.7 (0.2, 1.0) -0.3 (-1.8, 0.9) -1.3 (-2.0, -0.7) H(2)= 20.87; p˂0.001; b*** c*** 
Category 
Switching 
  0.0 (-0.7, 1.0) -0.3 (-1.4, 0.8) -3.0 (-3.0, -2.8) H(2)= 19.99; p˂0.001; b*** c*** 
Trails B   0.4 (-0.2, 0.6) -0.6 (-1.6, 0.6) -3.0 (-3.0, -2.9) H(2)= 20.30; p˂0.001; b*** c*** 
Stroop 
Interference 
  0.5 (-0.3, 0.8) -0.3 (-1.1, 0.4) -3.0 (-3.0, -2.2) H(2)= 20.98; p˂0.001; b*** c*** 
Domain Score   0.1 (-0.1, 0.8) -0.4 (-0.9, 0.3) -2.2 (-2.5, -1.8) H(2)= 24.11; p˂0.001; b*** c*** 
Learning and Memory       
CVLT Free Recall -0.1 (-0.3, 0.6) -0.8 (-1.1, 0.0) -2.5 (-3.0, -1.6) H(2)= 21.83; p˂0.001; b*** c*** 
CVLT Short Delay -0.3 (-1.0, 0.5) -1.0 (-1.1, 0.5) -2.0 (-2.5, -1.5) H(2)= 18.99; p˂0.001; b*** c*** 
CVLT Long Delay  0.3 (-0.7, 1.0)   0.0 (-1.1, 0.0) -1.5 (-1.6, -1.0) H(2)= 14.33; p˂0.001; b*** 
Rey Immediate -0.2 (-0.9, 0.8) -1.7 (-2.3, -1.1) -1.9 (-2.6, -1.6) H(2)= 11.37; p˂0.005; b*** 
Rey Delayed -0.8 (-1.3, 1.2) -2.3 (-2.6, -1.6) -2.3 (-2.5, -1.4) H(2)= 14.44; p˂0.005; a*** b*** 
Domain Score  0.1 (-0.7, 0.3) -0.7 (-1.2, -0.7) -1.9 (-2.1, -1.8) H(2)= 22.51; p˂0.001; b*** c*** 
Visuospatial           
JOL   0.0 (-0.4, 0.4) -1.4 (-1.78, -0.9) -1.5 (-2.3, -0.6) H(2)=  8.95;  p˂0.05; b*** c*** 
VOSP   1.0 (0.0, 1.0)   0.0 (-1.0, 0.0) -1.3 (-2.5, 0.0) H(2)= 12.13; p˂0.005; b*** 
Picture 
Completion 
  1.0 (0.5, 1.3)   0.0 (-0.8, 0.2) -1.0 (-1.5, -1.0) 
H(2)= 21.98; p˂0.001; a*** b*** 
c*** 
Rey Copy -0.3 (-0.6, 0.3) -0.16 (-2.5, 0.8) -2.5 (-3.0, -1.0) H(2)=  7.12;  p˂0.05; b*** 
Domain Score   0.3 (-0.3, 0.6) -0.7 (-0.9, -0.3) -1.5 (-2.3, -0.8) H(2)= 20.40; p˂0.001; a*** b*** 
Language           
Boston Naming 0.8 (0.8, 0.9)   0.5 (-0.4, 0.8)   0.0 (-1.6, 0.6) H(2)= 5.72; p= 0.056 
ADAS-Cog- 
Language 
0.3 (-0.7, 0.3) -0.2 (-1.3, 0.3) -1.7 (-2.7, -1.2) H(2)= 13.43; p˂0.001; b*** 
DRS-2 -Language 0.3 (-0.7, 0.3)   0.3 (-0.2, 0.3) -1.3 (-2.2, -0.4) H(2)= 8.65; p˂0.01; b** c** 
Domain Score 1.8 (0.1, 0.3) -0.3 (-0.6, 0.4) -1.0 (-1.8, -0.7 H(2)= 18.38; p˂0.001; b*** c*** 
Global Z Score 0.1 (-0.2, 0.3) -0.6 (-0.8, -0.4) -1.9 (-2.1, -1.6) 
H(2)= 26.37; p˂0.001; a*** b*** 
c*** 
Note: Values are reported as median (Md), and the upper and lower bounds of the interquartile range (Lower 
quartile= Q1; Upper quartile= Q3). Domain z-scores for Attention, Working Memory and Processing Speed, Executive 
Function, Learning and Memory, Visuospatial functioning and Language are expressed as an aggregate score by 
averaging standardised scores from each measure per cognitive domain. Global Cognition Z score was expressed by 
an aggregate Z score by averaging standardised scores in five cognitive domains: Attention, Working Memory and 
Processing Speed, Executive Function, Learning and Memory, Visuospatial and Language. Analyses/Analysis of 
variance: Kruskal-Wallis. Post hoc pairwise comparison/Conover-Iman test between: a= PDN v PDMCI; b= PDN v PDD; 
c= PDMCI v PDD; * p< 0.05; ** p< 0.01; ***p<0.005. 
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3.3. Parkinson’s disease characterised by the interRAI-HC 
3.3.1. Outcome Measures of the interRAI-HC   
Table 3-3 summarises the outcome measures of cognition (CPS), activities of daily living 
(ADL –Long Form; IADL Performance Scale; IADL Capacity Scale), depression (DRS), and 
pain in the interRAI-HC. There were no significant group differences observed on any of 
these measures, although the IADL Performance Scale and IADL Capacity Scale neared 
significance (p=0.06), reflecting median scores lower for PDN than PDMCI (Md=14.5, Md= 
29.5), and PDMCI than PDD (Md=29.5, Md=33.5). There was a limited range of scores 
observed in measures of cognition (Md= 2.0; Q1= 0.25; Q3=2.0; score range of CPS is 0-6), 
activities of daily living (Md= 0.0; Q1= 0.0; Q3= 4.0; score range of ADL-Long form is 0-28), 
and depression (Md= 0.0; Q1= 0.00; Q3= 2.00; score range of DRS is 0-14).  
Table 3-3 
Clinical characteristics as assessed by the interRAI-HC Outcome Scales (n=31) 
 PDN          
(n = 12) 
PDMCI       
(n= 9) 
PDD                
(n= 13) 
Analyses 
 Md (Q1, Q3) Md (Q1, Q3) Md (Q1, Q3)  
CPS 1.0 (0.0, 2.0) 1.0 (0.0, 2.0) 2.0 (1.0, 2.0) H(2)=2.70, p=0.22 
Cognition total 1.0 (0.0, 1.0) 1.0 (0.0, 2.0) 2.0 (0.8, 3.0) H(2)= 3.93, p= 0.12 
ADL Long Form 0.0 (0.0, 2.8) 0.0 (0.0, 4.5) 0.0 (0.0, 4.0) H(2)= 0.04, p=0.98 
IADL Perform d 14.5 (8.0, 25.0) 29.5 (21.5, 41.0) 33.5 (29.0, 36.0) H(2)= 5.71, p=0.06 
IADL Capacity d 14.5 (6.0, 24.0) 30.5 (21.5, 40.5) 33.0 (29.0, 42.0) H(2)=5.49, p=0.06 
DRS 0.0 (0.0, 1.8) 0.0 (0.0, 2.0) 0.0 (0.0, 1.5) H(2)=0.13, p=0.92 
Pain 2.0 (0.0, 2.0) 1.0 (0.0, 2.0) 1.0 (0.0, 2.0) H(2)= 0.73, p= 0.67 
Note: d only MDS-HC NEW data available (n=16).  Values are reported as median (Md), and the upper and 
lower bounds of the interquartile range (Lower quartile= Q1; Upper quartile= Q3). Cognition: CPS –Cognitive 
Performance Scale (0-6); Cognition Total Score was expressed as an aggregate score totalling the first 3 scores 
recorded in Section C: Cognition of the interRAI-HC (0-7; C1: Cognitive Skills for Daily Decision Making, C2a. 
Short term Memory and C2b. Procedural Memory). Activities of Daily Living: ADL Long Form –Activities of Daily 
Living –Long Form (0-28); IADL –Performance –Instrumental Activities of Daily Living –Performance (0-48); IADL 
–Capacity –Instrumental Activities of Daily Living –Capacity (0-48). Mood and Psychiatric Symptoms: DRS –
Depression Rating Scale (0-14); Clinical Symptoms: Pain Scale (0-3). Analyses/Analysis of variance: Kruskal-
Wallis. 
Correlational analyses were used to measure the relationship between the CPS, the MMSE, 
MoCA and global cognition. The CPS has been validated against the MMSE (Morris et al., 
1994) and equivalent scores between the two measures are noted in the literature (interRAI, 
2013; Wellens et al., 2013). In this study, there was no significant association between the 
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MMSE and the CPS (rs(29)= -0.32, p=0.08), the CPS and the MoCA (rs(29)= -0.25, p=0.18) 
or the CPS and the global cognition z-score (rs(29)= -0.05, p= 0.78).  
See Figure 3-1, Figure 3-2 and Figure 3-3 for the pairwise scatterplots comparing the 
MMSE, MoCA and global cognition to the CPS. In Figure 3-1 a number of PDN patients 
were identified as “Mild” on the CPS, alongside PDD patients (see Appendix D). Also, the 
patient receiving the lowest score on the MMSE (20) and identified as PDD in this study, was 
identified on the CPS as cognitively “Intact”. Distribution of scores comparing the CPS to the 
MoCA and global cognition show a similar trend, with a scatter of scores in the CPS across 








Figure 3-1, Figure 3-2, and Figure 3-3:  Association between the CPS and global measures of cognitive assessment 
Note: Interpretation of Cognitive Performance Scale: 0= “Intact”, 1= “Borderline Intact”, 1= “Mild”, 2= “Moderate”, 3= 
“Moderate”, 4= “Moderate Severe”, 5= “Severe”, 6= “Very Severe”; CPS and MMSE equivalent scores: 0= 25, 1= 22, 2= 20, 3= 
15, 4= 7, 5= 5, 6= 0.5; Legend: PDN= open circle; PDMCI= square; PDD= closed circle; Global cognition= Combined global 




As previous analyses of variance showed the IADL Performance measure and IADL 
Capacity measure each neared significance (p=0.06), additional analyses were completed to 
evaluate the association between these scales and similar measures of ADL. The IADL 
Performance Scale assesses an individual’s ability to perform tasks related to independent 
functioning, while the IADL Capacity Scale is the presumed ability speculated by the 
assessor (interRAI, 2009).  
Correlational analyses showed there was a significant correlation between both of these 
measures and the ADL-IS; the IADL Performance rs(14)= 0.63; p<0.01 and IADL Capacity 
scale rs(14)= 0.64, p<0.01.  Figure 3-3 and Figure 3-4 show the pairwise scatterplots for 
IADL Performance and IADL Capacity as compared to the ADL-IS across groups. Trends in 
these graphs show a coherence between each IADL measure and the ADL-IS, with PDN 
scoring lower both on the IADL measure and ADL-IS, whilst the PDD group show increased 




Figure 3- 4 and Figure 3-5: Association between the IADL Performance Scale and the ADL-IS 
(p<0.01) and the IADL Capacity Scale and the ADL-IS (p<0.01) 
Note: Legend: PDN= open circle; PDMCI= square; PDD= closed circle 
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3.3.2. Individual items  
3.3.2.1. Diagnoses, Continence and Health Conditions 
Table 3-4 summarises the frequency of disease diagnoses, continence and health condition 
data for each group. Some 33 of the 34 participants in the study were accurately classified 
with a Parkinson’s disease diagnosis, however only 6% of the sample were identified as 
having dementia other than AD. Of the two participants identified as having dementia by the 
interRAI-HC, one was classified as PDN by this study. PDN and PDMCI were completely 
bowel continent, and largely without difficulties with excessive amounts of sleep (PDN=88%; 
PDMCI= 100%). PDMCI however showed increased difficulty falling asleep (PDN= 88%; 
PDMCI= 50%), while PDN showed an increased level of pain. PDD patients had a significant 
increase in falls experienced in the last 90 days (p<0.005). They also experienced an 
increase in bladder incontinence (PDN= 50%; PDMCI= 22%; PDD= 69%) and difficulty 
getting up from a standing position (PDN= 38%; PDMCI= 50%; PDD= 67%), although this 
was not a significant different from other groups. All groups showed difficulty with unsteady 
gait (PDN= 88%; PDMCI= 100%; PDD= 100%) and fatigue (PDN= 88%; PDMCI= 100%; 
















Items measuring disease diagnosis, continence and health in the interRAI-HC (n=34) 
 PDN          
(n = 12) 
PDMCI       
(n= 9) 
PDD                
(n= 13) 
Analyses 
 n (%) n (%) n (%)  
Section I: Disease diagnosis    
Parkinson’s disease 11 (91.7) 9 (100.0) 13 (100.0)  
Dementia other than AD 1 (8.3) 0 (0.0) 1 (7.7)  
Anxiety 2 (16.7) 0 (0.0) 1 (7.7)  
Depression 3 (25.0) 1 (11.1) 0 (0.0)  
Schizophrenia 0 (0.0) 0 (0.0) 0 (0.0)  
Section H: Continence        
Bladder Continence        
Continent 6 (50.0) 7 (77.9) 4 (30.7) p= 0.12 
Not Continent 6 (50.0) 2 (22.2) 9 (69.3)  
Bowel Continence        
Continent 12 (100.0) 9 (100.0) 11 (84.6) p= 0.32 
Not Continent 0 (0.0) 0 (0.0) 2 (15.4)  
Section J: Health Conditions      
Experienced falls in the last 90 days   
No Fall 7 (58.3) 8 (88.9) 2 (15.4) p<0.005 
Falls 5 (41.7) 1 (11.1) 11 (84.6) b* c*** 
Difficult or unable to move self to standing position unassisted d  
Not present 5 (62.5) 1 (50.0) 2 (33.3) p=0.78 
Exhibited in the last 3 days 3 (37.5) 1 (50.0) 4 (66.7)  
Unsteady gait d        
Not present 1 (12.5) 0 (0.0) 0 (0.0) p= 1.00 
Exhibited daily last 3 days 7 (87.5) 2 (100.0) 6 (100.0)  
Difficulty falling asleep; non-restful sleep     
Not present 7 (87.5) 1 (50.0) 3 (50.0) p= 0.24 
Exhibited daily last 3 days 1 (12.5) 1 (50.0) 3 (50.0)  
Excessive amounts of sleep      
Not present 7 (87.5) 2 (100.0) 5 (83.3) p= 1.00 
Exhibited daily last 3 days 1 (12.5) 0 (0.0) 1 (16.7)  
Fatigue d        
Not present 1 (12.5) 0 (0.0) 1 (16.7) p= 1.00 
Exhibited in the last 3 days 7 (87.5) 2 (100.0) 5 (83.3)  
Intensity of pain        
No pain 4 (33.3) 4 (44.4) 5 (38.5) p= 0.69 
Mild 0 (0.0) 1 (11.1) 3 (23.1)  
Moderate 5 (41.7) 4 (44.4) 4 (30.7)  
Severe 2 (16.7) 0 (0.0) 1 (7.7)  
Excruciating 1 (8.3) 0 (0.0) 0 (0.0)  
Note: d only MDS-HC NEW data available (n=16). Post hoc comparison using Fisher’s Exact between: a= PDN v 





The interRAI-HC measures of falls experienced in the last 90 days was compared to the 
ADL-IS, the MoCA and global cognition presented in Figure 3-5 and Figure 3-6. There was 
no significant difference between falls in experienced in the last 90 days and the ADL-IS 
(t(32)= -1.62, p= 0.11) or the MoCA (t(32)= 2.03, p=0.05). However there was a significant 
difference between falls experienced in the last 90 days and global cognition (t(32)=2.73, 
p<0.05). These results indicate that those who experienced a fall also received a lower 
global cognition z-score than those who has not fallen in the last 90 days. Although this 
difference was not statistically significant for scores on the ADL-IS or the MoCA, there is a 
similar trend from the scatterplots which show those who experienced falls also tended to 















Figure 3-6, Figure 3-7 and Figure 3-8: Association between falls experienced in the last 90 days and 
ADL-IS, the MoCA, and global cognition 




3.3.2.2. Cognition  
As no group differences were observed in the outcome measures of cognition from the 
interRAI-HC, item-by-item analyses of Section C: Cognition were completed and are 
summarised in Table 3-5. The majority of PDN and PDMCI participants tended to be 
described as “Independent” in cognitive skills needed for daily decision making (67% and 
78% respectfully) alongside 62% of PDD. All of PDN and PDMCI participants were identified 
as having “Okay” situational memory, along with 83% of those with PDD. A number of 
PDMCI and PDD participants both indicated a noticeable change in their decision making 
ability in the last 90 days (PDMCI=89%; PDD= 62%) compared to PDN (33%), and less 
PDMCI and PDD reported an ability to understand others (PDMCI=67%; PDD= 69%) 
compared to PDN (92%). A significant group difference was seen in the measure of 
procedural memory (p<0.05), with all PDN participants indicating no problem with procedural 
memory compared to 39% of PDD (post hoc analysis: PDN v PDD= p<0.01). 
 
Table 3-5 
Items measuring cognitive symptoms in the interRAI-HC (n= 34) 
 
PDN          
(n = 12) 
PDMCI       
(n= 9) 
PDD                
(n= 13) 
Analyses 
 n % n % n %  
Section C: Cognition        
Cognitive Skills for Daily Decision Making  
Independent 8 (66.7) 7 (77.8) 8 (61.5) p=0.30 
Modified independence 3 (25.0) 1 (11.1) 1 (7.7)  
Minimally impaired 1 (8.3) 0 (0.0) 4 (30.8)  
Moderately impaired 0 (0.0) 1 (11.1) 0 (0.0)  
Severely impaired 0 (0.0) 0 (0.0) 0 (0.0)  
Short Term Memory        
Memory Okay 8 (66.7) 4 (44.4) 3 (23.1) p= 0.10 
Memory problem 4 (33.3) 5 (55.6) 10 (76.9)  
Procedural Memory        
Memory Okay 12 (100.0) 7 (77.8) 8 (61.5) p<0.05 
Memory problem 0 (0.0) 2 (22.2) 5 (38.5) b** 
Situational Memory d        
Memory Okay 8 (100.0) 2 (100.0) 5 (83.3) p= 0.50 
Memory problem 0 (0.0) 0 (0.0) 1 (16.7)  
Change in decision making in 90 days   
Change 4 (33.3) 8 (88.9) 8 (61.5) p= 0.07 
No change 7 (58.3) 1 (11.1) 5 (38.5)  
Uncertain 1 (8.3) 0 (0.0) 0 (0.0)  
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Making self-understood (Expression)     
Understood 7 (58.3) 6 (66.7) 7 (53.9) p= 0.74 
Usually understood 5 (41.7) 2 (22.2) 4 (30.8)  
Often understood 0 (0.0) 1 (11.1) 2 (15.4)  
Sometimes understood 0 (0.0) 0 (0.0) 0 (0.0)  
Rarely understood 0 (0.0) 0 (0.0) 0 (0.0)  
Ability to understand others (Comprehension)  
Understands 11 (91.7) 6 (66.7) 9 (69.2) p= 0.56 
Usually understands 1 (8.3) 2 (22.2) 2 (15.4)  
Often understands 0 (0.0) 1 (11.1) 2 (15.4)  
Sometimes understands 0 (0.0) 0 (0.0) 0 (0.0)  
Rarely understands 0 (0.0) 0 (0.0) 0 (0.0)  
Note: d only MDS-HC NEW data available (n=16). Post hoc comparison using Fisher’s Exact between: a= PDN v 
PDMCI; b= PDN v PDD; c= PDMCI v PDD; * p< 0.05; ** p< 0.01; ***p<0.005 
 
Correlational analyses were completed to investigate whether cognitive skills for daily 
decision making (Section C: 1.), short-term memory (Section C; 2a.) and procedural memory 
(Section C: 2b.) in the interRAI-HC were significantly associated with similar measures.  
Cognitive skills for decision making is operationalised as a person’s ability to make decisions 
of daily living, such as planning and organisation (interRAI, 2009). Scores from this item 
were compared to the combined z-score for executive functioning (Figure 3-7) and the global 
cognition z-score (Figure 3-8). Correlational analyses showed there was not a significant 
association between cognitive skills for decision making and executive functioning (rs(32)= -
0.17, p=0.34) or with global functioning (rs(32)= -0.11, p=0.52).  Due to the ambiguity of 
definition for this construct, an additional analysis was conducted with the ADL-IS. There 




Figure 3-9 and Figure 3-10: Association between cognitive skills for decision making and executive 
functioning, and global cognition 
Note: Legend: PDN= open circle; PDMCI= square; PDD= closed circle; Executive Functioning= Executive 
functioning combined z-score; Global cognition= Combined global cognition z-score 
 
Short term memory in the interRAI-HC is defined as recall after five minutes, and although 
examples are given, no standardised method of assessment is operationalised (interRAI-HC, 
2009). The item of short term memory was compared to the combined z-score of learning 
and memory (Figure 3-9) and the global cognitive z-score (Figure 3-10).  An independent 
sample t-test observed a significant difference of short-term memory on the interRAI-HC with 
learning and memory (r(32)= -0.43; p<0.05). Similarly, there was a significant difference of 
short-term memory and global cognition (r(32)= -0.39; p<0.05). This result indicates that 
those who had a problem of short-term memory received lower scores in both the learning 
and memory domain, and global cognition domain, than those who were not identified as 




Figure 3-11 and Figure 3-12: Association between short term memory and learning and memory, and global 
cognition 
Note: Legend: PDN= open circle; PDMCI= square; PDD= closed circle; Learning and Memory= Learning and 
Memory combined z-score; Global cognition= Combined global cognition z-score 
 
Procedural memory is measured in the interRAI-HC as the cognitive ability to perform 
sequential activities and recall one step in order to perform the next step (interRAI, 2009). 
Scores of procedural memory were compared to the combined z-score for attention and 
working memory (Figure 3-11) and the global cognition z-score (Figure 3-12). The interRAI-
HC identified all PDN participants as possessing intact procedural memory. However 62% of 
PDD patients were also classified as unimpaired, with several participants showing scores 
2SD below normal range. A t-test of independent samples showed there was no significant 
difference of procedural memory associated with attention and memory (t(32)= -1.83, p=0.8), 
but a significant difference between procedural memory and global cognition (r(32)= -0.35; 
p<0.05). This result shows that those who indicate having a problem of procedural memory 
also scored lower in global cognition, as compared to those whose procedural memory was 





Figure 3-13 and Figure 3-14: Association between short term memory and learning and memory, and global 
cognition z-scores 
Note: Legend: PDN= open circle; PDMCI= square; PDD= closed circle; Attention and Memory= Attention and 
Memory combined z-score; Global cognition= Combined global cognition z-score 
 
3.3.2.3. Functional Independence –ADLs and IADLs 
As previous noted, significant group differences were not observed between the interRAI-HC 
outcome measures of ADL (ADL Long Form) or IADL (IADL Performance, IADL Capacity). 
Similarly no significant differences were seen after tests of independence on individual items 
of Section G: Functional status in the interRAI-HC.  
Table 3-6 summarises the frequency of IADL performance for each group. More PDD 
participants required assistance with meal preparation (85%), managing medications (69%), 
and using the telephone (31%) as compared to PDN (42%, 33%, and 17% respectively). 
That said, both PDD and PDN required assistance managing finances (77% and 67%), and 
similar need was seen across groups for shopping (PDN= 50%, PDMCI=67%, PDD=69%) 
and using the stairs (PDN= 42%, PDMCI, 44%, PDD= 54%). Increased frequency of 
assistance was indicated for PDN as compared to PDMCI and PDD for transportation (25%, 






Items measuring performance of instrumental activities of daily living in the interRAI-HC (n= 
34) 
 
PDN          
(n = 12) 
PDMCI       
(n= 9) 
PDD                
(n= 13) 
Analyses 
 n (%) n (%) n (%)  
Section G: Functional Status  
IADL Self-Performance  
Meal Preparation        
Independent 5 (41.7) 3 (33.3) 1 (7.7) p= 0.15 
Assistance 5 (41.7) 6 (66.7) 11 (84.6)  
Did not occur 2 (16.6) 0 (0.0) 1 (7.7)  
Ordinary Housework        
Independent 2 (16.7) 1 (11.1) 1 (7.7) p= 1.00 
Assistance 10 (83.3) 8 (88.9) 11 (84.6)  
Did not occur 0 0.00 0 (0.0) 1 (7.7)  
Managing Finances        
Independent 4 (33.3) 5 (55.6) 2 (15.4) p= 0.21 
Assistance 8 (66.7) 4 (44.4) 10 (76.9)  
Did not occur 0 (0.0) 0 (0.0) 1 (7.7)  
Managing Medications        
Independent 8 (66.7) 6 (66.7) 4 (30.8) p= 0.13 
Assistance 4 (33.3) 3 (33.3) 9 (69.2)  
Phone Use        
Independent 10 (83.3) 8 (88.9) 9 (69.2) p= 0.57 
Assistance 2 (16.7) 1 (11.1) 4 (30.8)  
Stairs        
Independent 4 (33.3) 4 (44.4) 2 (15.4) p= 0.65 
Assistance 5 (41.7) 4 (44.4) 7 (53.9)  
Did not occur 3 (25.0) 1 (11.1) 4 (30.8)  
Shopping     
Independent 6 (50.0) 3 (33.3) 3 (23.1) P= 0.55 
Assistance 6 (50.0) 6 (66.7) 9 (69.2)  
Did not occur 0 (0.0) 0 (0.0) 1 (7.7)  
Transportation        
Independent 8 (66.7) 5 (55.6) 3 (23.1) p= 0.12 
Assistance 3 (25.0) 4 (44.4) 9 (69.2)  
Did not occur 1 (8.3) 0 (0.0) 1 (7.7)  
Note: d only MDS-HC NEW data available (n=16). Analyses: Fisher’s Exact. 
 
Table 3-7 summarises frequency of performance of ADLs for each group. All of the PDD 
group indicated they can walk independently, compared to 50% of PDN and PDMCI. All of 
the PDD sample also identified independent locomotion, compared to 50% of PDMCI and 
63% of PDN. Difficulty with toilet use (PDN= 25%, PDMCI, 11%, PDD= 23%), bed mobility 
(PDN= 25%, PDMCI= 22%, PDD= 15%) and eating (PDN= 0%, PDMCI= 11%, PDD= 7%) 
were similar across groups. However PDMCI and PDD required more assistance bathing 




Items measuring performance of activities of daily living in the interRAI-HC (n= 34) 
 
PDN          
(n = 12) 
PDMCI       
(n= 9) 
PDD                
(n= 13) 
Analyses 
 n % n % n %  
Section G: Functional Status        
ADL self-performance        
Bathing  
Independent 8 (66.7) 3 (33.3) 6 (46.2) p= 0.32 
Assistance 4 (33.3) 6 (66.7) 7 (53.8)  
Personal Hygiene        
Independent 8 (66.7) 7 (77.8) 8 (61.5) p= 0.81 
Assistance 4 (33.3) 2 (22.2) 5 (38.5)  
Dressing Upper Body        
Independent 8 (66.7) 6 (66.7) 7 (53.8) p= 0.82 
Assistance 4 (33.3) 3 (33.3) 6 (46.2)  
Dressing Lower Body        
Independent 8 (66.7) 6 (66.7) 6 (46.2) p= 0.56 
Assistance 4 (33.3) 3 (33.3) 7 (53.8)  
Walking d        
Independent 4 (50.0) 1 (50.0) 6 (100.0) p= 0.13 
Assistance 4 (50.0) 1 (50.0) 0 (0.0)  
Locomotion d        
Independent 5 (62.5) 1 (50.0) 6 (100.0) p= 0.18 
Assistance 3 (37.5) 1 (50.0) 0 (0.0)  
Transfer Toilet        
Independent 6 (75.0) 1 (50.0) 5 (83.3) p= 0.77 
Assistance 2 (25.0) 1 (50.0) 1 (16.7)  
Toilet Use        
Independent 9 (75.0) 8 (88.9) 10 (76.9) p= 0.76 
Assistance 3 (25.0) 1 (11.1) 3 (23.1)  
Bed Mobility        
Independent 9 (75.0) 7 (77.8) 11 (84.6) p= 0.87 
Assistance 3 (25.0) 2 (22.2) 2 (15.4)  
Eating        
Independent 12 (100.0) 8 (88.9) 12 (92.3) p= 0.722 
Assistance 0 (0.0) 1 (11.1) 1 (7.7)  
Note: d only MDS-HC NEW data available (n=16). Analyses: Fisher’s Exact. 
3.3.2.4. Neuropsychiatric symptoms 
As previous noted, significant group differences were not observed between the interRAI-HC 
outcome measures of depression (DRS). Similarly there were no significant differences of 
abnormal thought processes, delusions or hallucinations across groups, or from item-by-item 
analysis of other neuropsychiatric symptoms in the interRAI-HC (Table 3-8). Those with PDD 
reported persistent anger with themselves or others (15%), unrealistic fears (8%), and 
repetitive health complaints (8%) compared with no individuals with PDN or PDMCI. While 
25% of those with PDN expressed anhedonia (reduced feelings of pleasure) compared to no 




Items measuring neuropsychiatric symptoms, mood, and behaviour in the interRAI-HC 
(n=34) 
 
PDN          
(n = 12) 
PDMCI       
(n= 9) 
PDD                
(n= 13) 
Analyses 
 n % n % n %  
Section J: Health Conditions        
Abnormal thought process d        
Present 1 (12.5) 0 (0.0) 1 (16.7) p= 1.00 
Not present 7 (87.5) 2 (100.0) 5 (83.3)  
Delusions d        
Present 1 (12.5) 1 (50.0) 1 (16.7) p= 0.49 
Not present 7 (87.5) 1 (50.0) 5 (83.3)  
Hallucinations d        
Present 1 (12.5) 1 (50.0) 2 (33.3) p= 0.40 
Not present 7 (87.5) 1 (50.0) 4 (66.7)  
Section E: Mood and Behaviour       
Made negative statements        
Present 1 (8.3) 0 (0.0) 2 (15.4) p= 0.77 
Not present 11 (91.7) 9 (100.0) 11 (84.6)  
Persistent anger with self or others      
Present 0 (0.0) 0 (0.0) 2 (15.4) p= 0.32 
Not present 12 (100.0) 9 (100.0) 11 (84.6)  
Expression of unrealistic fears       
Present 0 (0.0) 0 (0.0) 1 (7.7) p= 1.00 
Not present 12 (100.0) 9 (100.0) 12 (92.3)  
Repetitive health complaints    
Present 0 (0.0) 0 (0.0) 1 (7.7) p= 1.00 
Not present 12 (100.0) 9 (100.0) 12 (92.3)  
Repetitive anxious concerns        
Present 1 (8.3) 1 (11.1) 1 (7.7) p= 1.00 
Not present 11 (91.7) 8 (88.9) 12 (92.3)  
Sad, pained, worried facial expressions       
Present 4 (33.3) 3 (33.3) 2 (15.4) p= 0.62 
Not present 8 (66.7) 6 (66.7) 11 (84.6)  
Crying and tearfulness     
Present 2 (16.7) 0 (0.0) 1 (7.7) p= 0.61 
Not present 10 (83.3) 9 (100.0) 12 (92.3)  
Recurrent statements something bad is going to happen d  
Present 0 (0.0) 0 (0.0) 0 (0.0) p= 1.00 
Not present 8 (100.0) 2 (100.0) 6 (100.0)  
Withdrawal from activities of interest  
Present 1 (8.3) 0 (0.0) 2 (15.4) p= 0.77 
Not present 11 (91.7) 9 (100.0) 11 (34.6)  
Reduced social interaction        
Present 2 )16.7) 1 (11.1) 2 (15.4) p= 1.00 
Not present 10 (83.3) 8 (88.9) 11 (34.6)  
Expressions of anhedonia d        
Present 2 (25.0) 0 (0.0) 0 (0.0) p= 0.60 
Not present 6 (75.0) 2 (100.0) 6 (100.0)  
Note: d only MDS-HC NEW data available (n=16). Analyses: Fisher’s Exact. 
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3.3.2.5. Additional non-motor symptoms and health indicators 
Additional items within the interRAI-HC were selected in order to explore other non-motor 
symptoms for this sample which may relate to cognitive status and disease pathology. There 
were no significant differences between groups observed in hearing, vision, loneliness or 
self-reported health. That said, more individuals with PDMCI reported “Excellent” health 
(78%), as compared to PDN (33%) and PDD (46%). Those with PDD also reported 
increased carer distress (15%), carer feeling overwhelmed (15%), and career being unable 
to continue (15%), than PDN participants (0%, 8%, 0% respectively) or PDMCI (0%, 0%, 
11% respectively). There were no significant differences detected in assessed elements of 
social support, with similar frequencies of informal helper/caregivers across groups, and 
















Additional items measuring non-motor symptoms and health in the interRAI-HC (n= 34) 
 
PDN          
(n = 12) 
PDMCI       
(n= 9) 
PDD                
(n= 13) 
Analyses 
 n % n % n %  
Section D: Communication and Vision     
Hearing        
Adequate 5 (41.7) 7 (77.8) 10 (76.9) p= 0.14 
Impaired 7 (58.3) 2 (22.2) 3 (23.1)  
Vision        
Adequate 11 (91.7) 9 (100.0) 10 (76.9) p= 0.42 
Impaired 1 (8.3) 0 (0.0) 3 (23.1)  
Section F: Psychosocial Well-being      
Lonely        
Yes 1 (8.3) 0 (0.0) 3 (23.1) p= 0.42 
No 11 (91.7) 9 (100.0) 10 (76.9)  
Section J: Health Conditions  
Self-Reported Health        
Excellent 4 (33.3) 7 (77.8) 6 (46.1) p= 0.18 
Good 4 (33.3) 0 (0.0) 3 (23.1)  
Fair 4 (33.3) 1 (11.1) 4 (30.8)  
Poor 0 (0.0) 1 (11.1) 0 (0.0)  
Section P: Social Supports        
Informal Helper/Caregiver        
Yes 11 (91.7) 6 (66.7) 10 (76.9) p= 0.37 
No 1 (8.3) 3 (33.3) 3 (23.1)  
Informal carer unable to continue care due to own health difficulties 
Yes 0 (0.0) 1 (11.1) 2 (15.4) p= 47 
No 12 (100.0) 8 (88.9) 11 (84.6)  
Informal carer expresses distress, anger, or depression   
Yes 0 (0.0) 0 (0.0) 2 (15.4) p= 0.32 
No 12 (100.0) 9 (100.0) 11 (84.6)  
Informal carer reports being overwhelmed by level of need    
Yes 1 (8.3) 0 (0.0) 2 (15.4) p= 0.77 
No 11 (91.7) 9 (100.0) 11 (84.6)  
Note: d only MDS-HC NEW data available (n=16). Analyses: Fisher’s Exact. 
 
3.4. Testing proximity and interRAI-HC format 
Additional analyses were completed to examine the impact of time between detailed 
neuropsychological testing and the interRAI-HC, and the different versions of the interRAI-
HC form that were collected in this study. 
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As there were <183 days between each testing condition, it is important to ascertain whether 
possible cognitive decline over this time period impacted these results. Analysis of variance 
showed no significant group differences in days between tests (H(2)=3.34, p= 0.19) and 
there was no significant association between testing proximity and global cognition z-score 
(rs(32)= -0.28, p= 0.11). See Figure 3-9 for the pairwise scatterplot of time between testing 
and the global z-score. A t-test of independent means was also completed to analyse 
whether having completed the interRAI-HC before or after detailed neuropsychological 
testing had an impact on global cognition z-score, which resulted in no significant differences 









Figure 3-14: Association of days between testing conditions and global cognition z-score  
Note: Legend: PDN= open circle; PDMCI= square; PDD= closed circle; Global cognition= Combined global 
cognition z-score 
 
A t-test of independent means was also completed to explore whether there was a difference 
in scores of cognition between the two forms of the interRAI-HC collected in this study 
(MDS-HC version 2.0 and interRAI-HC version 9.1). There was no significant difference in 
scores of the MDS-HC and the interRAI-HC on the CPS (t(29)=0.24, p=0.81), cognition in 
daily decision making (t(29)= 0.12, p=91), short term memory (t(29)=0.21, p=0.84) or 






This research compared the characterisation of cognitive functioning, motor symptoms and 
non-motor symptoms in PD by the interRAI-HC with a battery of detailed neuropsychological 
tests. Participants in this study were classified by cognitive status using current MDS criteria 
to evaluate whether the interRAI-HC could identify differences of functioning between these 
groups, to reflect the differences of need indicated by research and seen in the community. 
This comparison also provided preliminary evaluation of the external validity of some 
corresponding interRAI-HC measures in the assessment of PD. 
As anticipated, characterisation of PD by detailed neuropsychological testing produced clear 
group differences of cognition, motor symptoms and non-motor symptom profile, which 
reflected expectations outlined in research. Results showed a clear progression of cognitive 
decline and functional independence between PDN and PDD, with PDMCI often identified as 
an intermediary stage of impairment. PDD exhibited worse performance compared to PDN 
on all but two neuropsychological tests (of which there were no significant differences), with 
particular impairment seen in tasks of executive functioning, attention and working memory, 
and learning and memory. Dementia in PD has been described as a cognitive profile of 
pronounced executive dysfunction (Emre et al., 2007) secondary to attention and memory 
deficits (Noe et al., 2004); this is reflected in the characterisation of neuropsychological tests 
for this sample. Additionally, those with PDD also showed increased motor symptoms 
compared to both PDN and PDMCI, however PDN and PDMCI did not differ. In this way, 
although PDMCI acted as an intermediary stage of decline for cognition and activities of 
daily living for this sample, PDMCI appeared to be less impacted by motor symptom burden 
in this sample. 
In the interRAI-HC, one participant failed to be identified with a diagnosis of PD, while 12 
PDD participants were not recognised as having dementia other than AD. This result is of 
interest, as the presence of disease diagnoses within this instrument will indicate the level of 
care needed and the type of intervention required for that individual (Morris et al., 2009).  
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Nearly every participant of each group reported difficulties with excessive fatigue and 
unsteady gait, which would be expected from the literature. There was also a statistically 
significant difference between groups in falls experienced in the last 90 days. In addition, 
those who experienced falls showed greater impairment on the global cognition z-score, 
which was statistically different from those who had not experienced falls. This result is of 
interest as the measurement of falls and fall risk was not included in the neuropsychological 
battery, and appears relevant to developing cognitive impairment in this population. 
In contrast to global measures in the neuropsychological battery, none of the outcome 
measures in the interRAI-HC were seen to significantly distinguish group differences in this 
sample. Despite these results, there are trends of agreement the characterisation of this 
sample by the interRAI-HC and neuropsychological testing. For example, PDD participants 
exhibited worse cognition than PDN and PDMCI on the CPS, short-term memory and 
procedural memory. Although this pattern was not significant on the CPS or short-term 
memory, the measure of procedural memory was able to significantly differentiate PDN from 
PDD, reflecting a similar pattern to neuropsychological testing and the expected profile from 
research. In contract to expectations, the item assessing “cognitive skills for daily decision 
making” identified almost as many PDD participants (62%) as PDN (67%) participants as 
cognitively “Independent”. In addition, this item did not significantly correlate with other 
measures of executive functioning, global cognition or the ADL-IS.  This result is of interest, 
as this item is used to form the final score of the CPS and may have contributed to the 
inability of the CPS to identify significant group differences. 
The CPS has been validated against the MMSE (Morris et al., 1994) and equivalent scores 
have been reported in the literature (Wellens et al., 2013). In this study, there was no 
significant association between the CPS and the MMSE, nor was an association seen 
between the CPS and the MoCA, or global cognition z-score. This result is of particular 
interest as agreement between the CPS and the MMSE would be expected. In addition, the 
43 
 
CPS failed to identify one PDD participant labelling him as cognitively “Intact”, despite him 
also receiving the lowest score on the MMSE (20). 
Similarly, there were mixed results in the characterisation of activities of daily living by the 
interRAI-HC. The ADL –Long Form showed little variance in scores across groups and 
identified all groups as “Independent” in the performance of activities of daily living (median 
score of zero for all groups, out of a total score of 48). This trend was not seen in 
neuropsychological testing, which saw a significant decline in functioning from PDN to 
PDMCI, and subsequently to PDD. However, this progressive decline of functional 
independence across groups was seen in interRAI-HC measures of IADL. In addition, both 
the IADL Performance Scale and the IADL Capacity Scale showed a significant relationship 
with the neuropsychological measure of activities of daily living (ADL-IS). This result is of 
particular promise, as it shows convergent validity between these measures despite a very 
small sample (interRAI-HC version 9.1. data only; n=16). 
Although group differences were indicated in the NPI, no group differences of abnormal 
thoughts, delusions or hallucinations were identified in the interRAI-HC. In addition, results 
from neither the interRAI-HC nor neuropsychological battery identified group differences in 
depression or anxiety, or indicated mood disturbances out of the normal range. Although 
depression is common in PD, it is complicated to assess as many features such as fatigue, 
psychomotor slowing, muted facial expression and flatted affect can also be manifestation of 
PD pathology (Pandya, Kubu and Giroux, 2008). 
4.1. Limitations and Future Directions 
Although this is an important initial exploratory study into the characterisation of PD by the 
interRAI-HC, there are several limitations to consider. Several measures in the interRAI-HC 
reflected trends which were expected from research and similar to the results seen in the 
neuropsychological battery, however very few interRAI-HC measures identified significant 
differences across groups. In this way, for this sample the interRAI-HC outcome measures 
fail to “evaluate an individual’s current clinical status as compared to gold measure 
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standards” (Morris et al., 2000). However due to the small sample size in this study, it is 
important to recognise these trends and results as preliminary indicators for PD in New 
Zealand. 
Another limitation is the proximity of each testing condition, and the recoding of each form of 
the interRAI-HC (version 2.0 and version 9.1). Although analyses showed there were no 
group differences in the time between testing conditions, it is important to recognise 
significant cognitive decline can occur within the 6 month criteria for this study. In addition, 
although consensus was indicated between the MDS-HC and the interRAI-HC (no significant 
group differences between outcome measures of each form), there are elements of each 
assessment that required significant recoding and aggregation of measures in order to 
ensure consistency. It is also important to recognise that no significant differences across 
each version of the interRAI form may reflect low sensitivity within individual measures and 
type II error. Improvements to measures and new items of potential value were often 
excluded from analysis, due to small sample size or coding inconsistencies.  
In addition, the nature of types of data collected in the neuropsychological battery and 
measures within the interRAI-HC meant a number of statistical analyses were utilised. It is 
expected that some statistical significance would be due to chance alone, therefore some of 
the reported significant results may be spurious.  
4.2. Future Directions 
The interRAI-HC assessment system involves three levels of assessment: individual item 
measurement (Morris, et al., 1997), Outcome Scales (Morris et al., 2000) and Clinical 
Assessment Protocols (CAPs; Hirdes et al., 2008). CAPs are designed to assist 
interpretation, highlight key issues and guide specified interventions for each individual care 
plan (Morris et al., 2009). Only the outcome measures and individual assessment items were 
included this study, as CAP data was unavailable. It is important that future exploratory 
studies of this nature consider CAP measures in conjunction with the complete interRAI-HC 
assessment instrument to evaluate the characterisation of chronic illness. Future 
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investigations must also evaluate the ability of the interRAI-HC to allocate appropriate 
community interventions to meet assessed need.  
Since the advent of this study, the CPS has been evaluated and revised to introduce the 
CPS2 (Morris et al., 2016). The revision of the CPS aimed to adjust the measure to expand 
the scale of the measure and make it more sensitive to early cognitive impairment (Morris et 
al., 2016). The failure of the CPS to identify early cognitive impairment and difference of 
cognition between PDN and PDD was of interest to this sample. Individual items of cognition 
which form the final score on the CPS were also examined in this study, and the item of 
“cognition in daily decision making” was indicated as a possible weakness for the CPS in this 
sample. In the development of the CPS2, the item “cognition in daily decision making” held 
the strongest correlation with scores on the MMSE (Morris et al., 2016). As this result was 
not seen in this study, it is important that further investigations review the CPS2 and its 
relevance in assessing early cognitive impairment in PD.  
Finally, further analysis utilising large scale or national datasets are required to continue to 
clarify the assessment of PD in the interRAI-HC. The discrepancy seen between the ADL –
Long Form and similar measures of IADL is of interest in this study, and further research to 
clarify the assessment of functional independence for PD may be of benefit. Due to the 
constellation of symptoms associated with PD accurate assessment is complex, particularly 
for cognition and functional independence. For example, classic PD symptoms such as 
fatigue, depression, psychomotor slowing and sleep disturbance can have a major impact on 
and individual’s cognitive ability, but can reflect impairment outside of pathological 
neurodegeneration of cognitive processes. This can lead to fluctuations of cognitive 
performance, reflecting motor and non-motor symptom severity rather than true cognitive 
performance. Similarly, motor symptoms in PD often impact an individual’s ability to perform 
activities of daily living, but can confuse motor impairment with cognitive decline. In this way, 
large scale analyses which clarify the assessment of ADL and IADL, alongside motor 
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symptoms and cognition is essential to clarify the accuracy of the interRAI-HC for use in PD, 
and may lead to further developments within the instrument to benefit all populations. 
4.3. Concluding remarks 
This study examined the characterisation of cognitive functioning, motor symptoms and non-
motor symptoms for PD using the interRAI-HC, and establish the relevance of this 
assessment system in the identification of PDN, PDMCI and PDD. Despite an inability of 
several measures to identify groups differences in this sample, the interRAI-HC IADL 
outcome scales, and individual item of falls and elements of cognition appear relevant to the 
differential presentation of cognitive status in PD. Due to the importance of comprehensive 
assessment in PD (Chaudhuri, Yates, Martinez-Martin, 2005), the interRAI-HC remains a 
potential assessment of interest for this population. However, additional large scale research 
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A11 AA4 Domicile Code: Domicile Code of usual living arrangement 
A12 CC5 HC1 RESIDENTIAL STATUS: Residential /Living status at time of assessment 
A13a CC6 HC1 LIVING ARRANGEMENT lives: a. Lives 
A13b O2a 
HC1 LIVING ARRANGEMENT 90 days change: b. As compared to 90 DAYS AGO (or 
since last assessment), person now lives with someone new 
A13c O2b 
HC1 LIVING ARRANGEMENT better off elsewhere: c. Person or relative feels that 
the person would be better off living elsewhere 
A14 CC4 
HC1 TIME SINCE LAST HOSPITAL STAY: Code for most recent instance in LAST 90 
DAYS 
A1d A1d HC1 NAME OF CLIENT Jr Sr: d. Jr/Sr 
A2 BB1 HC1 SEX: 
A3 BB2a HC1 BIRTH DATE: 
A4 BB4 HC1 MARITAL STATUS: 
A5a AA2 NUMERIC IDENTIFIERS A5a: a. National Health Identifier (NHI) number 
A5c AA3 ACC Claim Number: c. ACC claim number 
A7a BB7a HC1 PAYMENT CATEGORIES a: a. New Zealand resident / citizen 
A7b BB7b HC1 PAYMENT CATEGORIES b: b. Work Visa 
A7c BB7c HC1 PAYMENT CATEGORIES c: c. Australian resident in NZ 
A7d BB7d HC1 PAYMENT CATEGORIES d: d. UK or Australian citizen visiting NZ 
A7e BB7e HC1 PAYMENT CATEGORIES e: e. ACC accepted claims 
A8 A2 HC1 REASON FOR ASSESSMENT: Primary reason for assessment 
A9 A1 HC1 ASSESSMENT REFERENCE DATE: 
B1 CC1 HC1 DATE CASE OPENED: 
B2a BB3ba ETHNICITY: 10 European not further defined 
B2b BB3bb ETHNICITY: 11 New Zealand European 
B2c BB3bc ETHNICITY: 12 Other European 
B2d BB3bd ETHNICITY: 21 Maori 
B2e BB3be ETHNICITY: 30 Pacific peoples not further defined 
B2f BB3bf ETHNICITY: 31 Samoan 
B2g BB3bg ETHNICITY: 32 Cook Island Maori 
B2h BB3bh ETHNICITY: 33 Tongan 
B2i BB3bi ETHNICITY: 34 Niuean 
B2j BB3bj ETHNICITY: 35 Tokelauan 
B2k BB3bk ETHNICITY: 36 Fijian 
B2l BB3bl ETHNICITY: 37 Other Pacific peoples 
B2m BB3bm ETHNICITY: 40 Asian not further defined 
B2n BB3bn ETHNICITY: 41 Southeast Asian 
B2o BB3bo ETHNICITY: 42 Chinese 
B2p BB3bp ETHNICITY: 43 Indian 
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B2q BB3bq ETHNICITY: 44 Other Asian 
B2r BB3br ETHNICITY: 51 Middle Eastern 
B2s BB3bs ETHNICITY: 52 Latin American / Hispanic 
B2t BB3bt ETHNICITY: 53 African (or any group of African origin) 
B2u BB3bu ETHNICITY: 61 Other ethnicity 
B2y BB3bv ETHNICITY: 99 Not stated 
B3 BB5a Primary language: Primary language (See manual for codes) 
B4a   
HC1 RESIDENTIAL HISTORY OVER LAST 5 YEARS Long-term care facility: a. Long-
term care facility—e.g., nursing home 
C1 B2a 
HC1 COGNITIVE SKILLS FOR DAILY DECISION MAKING: Making decisions regarding 
tasks of daily life—e.g., when to get up or have meals, which clothes to 
C2a B1a 
MEMORY RECALL ABILITY a: a. Short-term memory OK—Seems / appears to recall 
after 5 minutes 
C2b B1b 
MEMORY RECALL ABILITY b: b. Procedural memory OK—Can perform all or 
almost all steps in a multitask sequence without cues 
C2c   
MEMORY RECALL ABILITY c: c. Situational memory OK—Both: recognises 
caregivers' names / faces frequently encountered AND knows 
C5 B2b CHANGE IN DECISION MAKING: 
D1 C2 
HC1 MAKING SELF UNDERSTOOD: Expressing information content—both verbal 
and non-verbal 
D2 C3 
HC1 ABILITY TO UNDERSTAND OTHERS : Understanding verbal information 
content (however able; with hearing aid normally used) 
D3 C1 HC1 HEARING: Ability to hear (with hearing aid normally used) 
D4 D1 
HC1 VISION: Ability to see in adequate light (with glasses or with other visual aid 
normally used) 
E1a E1a 
HC1 INDICATORS OF DEPRESSION a: a. Made negative statements—e.g., "Nothing 
matters"; "Would rather be dead"; "What’s the use"; "Re 
E1b E1b 
HC1 INDICATORS OF DEPRESSION b: b. Persistent anger with self or others—e.g., 
easily annoyed, anger at care received 
E1c E1c 
HC1 INDICATORS OF DEPRESSION c: c. Expressions, including nonverbal, of what 
appear to be unrealistic fears—e.g., fear of being ab 
E1d E1d 
HC1 INDICATORS OF DEPRESSION d: d. Repetitive health complaints—e.g., 
persistently seeks medical attention, incessant concern with 
E1e E1e 
HC1 INDICATORS OF DEPRESSION e: e. Repetitive anxious complaints / concerns 
(non-health-related) e.g., persistently seeks attention 
E1f E1f 
HC1 INDICATORS OF DEPRESSION f: f. Sad, pained, or worried facial expressions—
e.g., furrowed brow, constant frowning 
E1g E1g HC1 INDICATORS OF DEPRESSION g: g. Crying, tearfulness 
E1h   
HC1 INDICATORS OF DEPRESSION h: h. Recurrent statements that something 
terrible is about to happen—e.g., believes he or she is about to die 
E1i E1h 
HC1 INDICATORS OF DEPRESSION i: i. Withdrawal from activities of interest—e.g., 
long-standing activities, being with family / friend 
E1j E1i HC1 INDICATORS OF DEPRESSION j: j. Reduced social interactions 
E3a E3a 
HC1 BEHAVIOUR SYMPTOMS a: a. Wandering—Moved with no rational purpose, 




HC1 BEHAVIOUR SYMPTOMS b: b. Verbal abuse—e.g., others were threatened, 
screamed at, cursed at 
E3c E3c 
HC1 BEHAVIOUR SYMPTOMS c: c. Physical abuse—e.g., others were hit, shoved, 
scratched, sexually abused 
E3d E3d 
HC1 BEHAVIOUR SYMPTOMS d: d. Socially inappropriate or disruptive behaviour 
— e.g., made disruptive sounds or noises, screamed 
E3f E3e 
HC1 BEHAVIOUR SYMPTOMS f: f. Resists care—e.g., taking medications / 
injections, ADL assistance, eating 
F1d F1b HC1 SOCIAL RELATIONSHIPS d: d. Conflict or anger with family or friends 
F1f   HC1 SOCIAL RELATIONSHIPS f: f. Neglected, abused, or mistreated 
F2 F3b HC1 LONELY: Says or indicates that he / she feels lonely 
F3 F2 
HC1 CHANGE IN SOCIAL ACTIVITIES: Decline in level of participation in social, 
religious, occupational, or other preferred activities. 
F4 F3a HC1 LENGTH OF TIME ALONE: (MORNING AND AFTERNOON) 
G1aa H1aA 
HC1 IADL SELF-PERFORMANCE AND CAPACITY aa: Meal Preparation  a. 
Performance 
G1ab H1aB HC1 IADL SELF-PERFORMANCE AND CAPACITY ab: Meal Preparation  b. Capacity 
G1ba H1bA 
HC1 IADL SELF-PERFORMANCE AND CAPACITY ba: Ordinary Housework a. 
Performance 
G1bb H1bB 
HC1 IADL SELF-PERFORMANCE AND CAPACITY bb: Ordinary Housework b. 
Capacity 
G1ca H1cA 
HC1 IADL SELF-PERFORMANCE AND CAPACITY ca: Managing Finances a. 
Performance 
G1cb H1cB HC1 IADL SELF-PERFORMANCE AND CAPACITY cb: Managing Finances b. Capacity 
G1da H1dA 
HC1 IADL SELF-PERFORMANCE AND CAPACITY da: Managing Medications a. 
Performance 
G1db H1dB 
HC1 IADL SELF-PERFORMANCE AND CAPACITY db: Managing Medications b. 
Capacity 
G1ea H1eA HC1 IADL SELF-PERFORMANCE AND CAPACITY ea: Phone Use a. Performance 
G1eb H1eB HC1 IADL SELF-PERFORMANCE AND CAPACITY eb: Phone Use b. Capacity 
G1fa H5 HC1 IADL SELF-PERFORMANCE AND CAPACITY fa: Stairs a. Performance 
G1fb H5 HC1 IADL SELF-PERFORMANCE AND CAPACITY fb: Stairs b. Capacity 
G1ga H1fA HC1 IADL SELF-PERFORMANCE AND CAPACITY ga:  Shopping a. Performance 
G1gb H1fB HC1 IADL SELF-PERFORMANCE AND CAPACITY gb:  Shopping b. Capacity 
G1ha H1gA HC1 IADL SELF-PERFORMANCE AND CAPACITY ha: Transportation a. Performance 
G1hb H1gB HC1 IADL SELF-PERFORMANCE AND CAPACITY hb: Transportation b. Capacity 
G2a H2j 
HC1 ADL SELF-PERFORMANCE a: a. Bathing—How takes a full-body bath / 
shower. Includes how transfers in and out of bath or shower 
G2b H2i 
HC1 ADL SELF-PERFORMANCE b: b. Personal hygiene—How manages personal 
hygiene, including combing hair, brushing teeth, shaving, a 
G2c H2e 
HC1 ADL SELF-PERFORMANCE c: c. Dressing upper body—How dresses and 
undresses (street clothes, underwear) above the waist 
G2d H2f 
HC1 ADL SELF-PERFORMANCE d: d. Dressing lower body—How dresses and 
undresses (street clothes, underwear) from the waist down, in 
G2h H2h 
HC1 ADL SELF-PERFORMANCE h: h. Toilet use—How uses the toilet room (or 




HC1 ADL SELF-PERFORMANCE i: i. Bed mobility—How moves to and from lying 
position, turns from side to side, and positions body 
G2j H2g 
HC1 ADL SELF-PERFORMANCE j: j. Eating—How eats and drinks (regardless of 
skill). Includes intake of nourishment by other means ( 
G4a H6b 
HC1 ACTIVITY LEVEL a: a. Total hours of exercise or physical activity in LAST 3 
DAYS—e.g., walking 
G4b H6a 
HC1 ACTIVITY LEVEL b: b. In the LAST 3 DAYS, number of days went out of the 
house or building in which he / she resides ( 
G5a H7a 
HC1 PHYSICAL FUNCTION IMPROVEMENT POTENTIAL a: a. Person believes he / 
she is capable of improved performance in physical function 
G6 H3 
Change in ADL status (0-3): As compared to 90 days ago, or since last assessment 
if less than 90 days ago 
H1 I1a HC1 BLADDER CONTINENCE: 
H2 I2b HC1 URINARY COLLECTION DEVICE: (Exclude pads / briefs) 
H3 I3 HC1 BOWEL CONTINENCE: 
H4 I2a HC1 PADS OR BRIEFS WORN: 
I1a J1n 
HC1 DISEASE DIAGNOSES a: a. Hip fracture during last 30 days (or since last 
assessment if less than 30 days) 
I1b J1o 
HC1 DISEASE DIAGNOSES b: b. Other fracture during last 30 days (or since last 
assessment if less than 30 days) 
I1c J1g HC1 DISEASE DIAGNOSES c: c. Alzheimer’s disease 
I1d J1h HC1 DISEASE DIAGNOSES d: d. Dementia other than Alzheimer’s disease 
I1e J1j HC1 DISEASE DIAGNOSES e: e. Hemiplegia 
I1f J1k HC1 DISEASE DIAGNOSES f: f. Multiple sclerosis 
I1h J1l HC1 DISEASE DIAGNOSES h: h. Parkinson’s disease 
I1j J1a HC1 DISEASE DIAGNOSES j: j. Stroke / CVA 
I1k J1c HC1 DISEASE DIAGNOSES k: k. Coronary heart disease 
I1l J1z HC1 DISEASE DIAGNOSES l: l. Chronic obstructive pulmonary disease 
I1m J1b HC1 DISEASE DIAGNOSES m: m. Congestive heart failure 
I1r J1u HC1 DISEASE DIAGNOSES r: r. Pneumonia 
I1s J1w HC1 DISEASE DIAGNOSES s: s. Urinary tract infection in last 30 days 
I1t J1x HC1 DISEASE DIAGNOSES t: t. Cancer 
I1u J1y HC1 DISEASE DIAGNOSES u: u. Diabetes mellitus 
J1 K5 HC1 FALLS: 
J6a K4a 
HC1 PAIN SYMPTOMS a: a. Frequency with which person complains or shows 
evidence of pain (including grimacing, teeth cle 
J6b K4b HC1 PAIN SYMPTOMS b: b. Intensity of highest level of pain present 
J7a K8b 
HC1 INSTABILITY OF CONDITIONS a: a. Conditions / diseases make cognitive, ADL, 
mood, or behaviour patterns unstable (fluctuating, pre 
J7b K8c 
HC1 INSTABILITY OF CONDITIONS b: b. Experiencing an acute episode, or a flare-
up of a recurrent or chronic problem 
J8 K8d HC1 SELF-REPORTED HEALTH: Ask: "In general, how would you rate your health?" 
K3 L3 HC1 MODE OF NUTRITIONAL INTAKE: 
K4c M1a HC1 DENTAL OR ORAL c: c. Reports having dry mouth 
K4d M1b HC1 DENTAL OR ORAL d: d. Reports difficulty chewing 
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L1 N2a HC1 MOST SEVERE PRESSURE ULCER: 
L2 N4 HC1 PRIOR PRESSURE ULCER: 
L3 N2b 
HC1 PRESENCE OF SKIN ULCER OTHER THAN PRESSURE ULCER: e.g., venous ulcer, 
arterial ulcer, mixed venous-arterial ulcer, diabetic foot ulcer 
L4 N1 
HC1 MAJOR SKIN PROBLEMS: e.g., lesions, 2nd- or 3rd-degree burns, healing 
surgical wound 
L5 N3c HC1 SKIN TEARS OR CUTS: Other than surgery 
L6 N3a 
HC1 OTHER SKIN CONDITIONS OR CHANGES IN SKIN CONDITION: e.g., bruises, 
rashes, itching, mottling, herpes zoster, intertrigo, eczema 
M3 Q4 HC1 ADHERENT WITH MEDICATIONS PRESCRIBED BY PHYSICIAN: 
N2a P2f HC1 TREATMENTS AND PROGRAMS a: 
N2b P2g HC1 TREATMENTS AND PROGRAMS b: 
N2e P2a HC1 TREATMENTS AND PROGRAMS e: 
N2f P2l HC1 TREATMENTS AND PROGRAMS f: 
N2i P2e HC1 TREATMENTS AND PROGRAMS i: 
N2j P2b HC1 TREATMENTS AND PROGRAMS j: 
N2m CC3f HC1 TREATMENTS AND PROGRAMS m: 
N4a P4a HC1 HOSPITAL USE a: a. Inpatient acute care hospital with overnight stay 
N4b P4b HC1 HOSPITAL USE b: b. Emergency room visit (not counting overnight stay) 
N4c P4c HC1 HOSPITAL USE c: c. Physician visit (or authorized assistant or practitioner) 
O1a BB6a HC1 LEGAL GUARDIAN a: a. EPOA for personal care and welfare 
O1b BB6a HC1 LEGAL GUARDIAN b: b. EPOA for property 
O2a BB6b HC1 ADVANCE DIRECTIVES a: a. Living will 
O2b BB6b HC1 ADVANCE DIRECTIVES b: b. Do not resuscitate 
O2c BB6b HC1 ADVANCE DIRECTIVES c: c. Do not hospitalise 
O2d BB6b HC1 ADVANCE DIRECTIVES d: d. Organ donation 
O2e BB6b HC1 ADVANCE DIRECTIVES e: e. Post mortem request 
O2f BB6b HC1 ADVANCE DIRECTIVES f: f. Feeding restrictions 
O2g BB6b HC1 ADVANCE DIRECTIVES g: g. Medication restrictions 
O2h BB6b HC1 ADVANCE DIRECTIVES h: h. Other treatment restrictions 
P1a1 G1fA HC1 INFORMAL HELPERS 1a: a. Relationship to person 
P1a2 G1fB HC1 INFORMAL HELPERS 2a: a. Relationship to person 
P1b1 G1gA HC1 INFORMAL HELPERS 1b: b. Lives with person 
P1b2 G1gB HC1 INFORMAL HELPERS 2b: b. Lives with person 
P1c1 G1hA HC1 INFORMAL HELPERS 1c: c. IADL help 
P1c2 G1hB HC1 INFORMAL HELPERS 2c: c. IADL help 
P1d1 G1iA HC1 INFORMAL HELPERS 1d: d. ADL help 
P1d2 G1iB HC1 INFORMAL HELPERS 1d: d. ADL help 
P2a G2a 
HC1 INFORMAL HELPER STATUS a: a. Informal helper(s) is unable to continue in 
caring activities—e.g., decline in health of helper m 
P2b G2c 
HC1 INFORMAL HELPER STATUS b: b. Primary informal helper expresses feelings 
of distress, anger, or depression 
P2c G2b 
HC1 INFORMAL HELPER STATUS c: c. Family or close friends report feeling 




HC1 HOURS OF INFORMAL CARE: For instrumental and personal activities of daily 
living in the LAST 3 DAYS, indicate the total numb 
Q1c O1e 
HC1 HOME ENVIRONMENT c: c. Inadequate heating or cooling—e.g., too hot in 
summer, too cold in winter 
Q1d O1f 
HC1 HOME ENVIRONMENT d: d. Lack of personal safety—e.g., fear of violence, 
safety problem in going to mailbox or visiting ne 
Q1e O1g 
HC1 HOME ENVIRONMENT e: e. Limited access to home or rooms in home—e.g., 
difficulty entering or leaving home, unable to clim 
R1 P5 HC1 ONE OR MORE CARE GOALS MET: 








































































Appendix F: Interpretation of the Depression Rating Scale (interRAI, 2015; 
http://www.interrai.org/assets/files/Scales/cognitive-performance-scale-2014.pdf) 
 
 
